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ABSTRACT Cardiovascular diseases (CVDs) and depression are the leading causes of mortality and disability worldwide, respectively; they are highly comorbid such that depression is 3 times more common in patients after an acute MI than the general population. Depression in patients who have CVD is associated with less adherence to secondary prevention treatments, poor health-related quality of life, and higher rates of adverse events, including mortality rates that are twice as high than those without depression. Patients prescribed antidepressants are often not monitored and screening is controversial, therefore identification and therapeutic response is suboptimal. This thesis is a secondary analysis of post-cardiac rehabilitation patients that explored the intersection of cardiac events and antidepressant use; specifically, the effects of medical history, depression status and antidepressant use on the likelihood of having major adverse cardiac events over a 10 year follow-up period. Antidepressant use was found to have a larger positive effect on depression status vs patients not on antidepressants; most patients were taking an SSRI as per guidelines and the degree of medication adherence was not associated with depressive symptoms. However, TCAs were most often associated with death outcomes, while SSRIs were significantly associated with non-lethal cardiac outcomes.  A review of antidepressant use by class in this population may be warranted.   
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INTRODUCTION 
Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide(Go et al., 2013; 
Yusuf, Reddy, Ounpuu, & Anand, 2001), and depression is the leading cause of disability 
worldwide(Mathers, Colin, Stevens, Gretchen, Mascarenhas, 2009), accordingly, they are highly 
comorbid (Thombs et al., 2005). Specifically, depression is approximately 3 times more common in 
patients after an acute myocardial infarction than in the general community (Ruo B, Rumsfeld JS, Hlatky 
MA, Liu H, Browner WS, 2009). It has been estimated that 30% of patients who have been hospitalized 
for a myocardial infarction experience elevated depressive symptoms, and 15-20% suffer from major 
depression (Geggel L, 2015; Halaris, 2009); this is at least 3 times the incidence of non-CVD patients, 
whose overall rate of depression is 3-5% globally (Milani & Lavie, 2007) . Women experience twice the 
rates of depression as men (Shanmugasegaram, Russell, Kovacs, Stewart, & Grace, 2012). Depression in 
patients who have CVD is associated with less adherence to secondary prevention treatments, poor 
health-related quality of life, and higher rates of adverse events, including mortality rates that are twice 
as high than those without depression (K. W. Davidson et al., 2010). 
Accordingly, the American Heart Association (Goff et al., 2014; Judith H Lichtman et al., 2008)  
recommends screening for depression in cardiac patients using the Patient Health Questionnaire 
(PHQ)(K Kroenke, Spitzer, & Williams, 2001). Cardiac rehabilitation (CR), which is a comprehensive 
outpatient program of secondary prevention and lifestyle counseling (Lett et al., 2004), includes 
assessment of depressive symptoms (Herridge, Stimler, Southard, & King, 2005; Rutledge, Redwine, 
Linke, & Mills, 2013). Indeed, psychological health is considered a core component of CR by many 
learned societies (AACVPR, 2013; Bjarnason-Wehrens et al., 2010; Buckley et al., 2013; Haddadzadeh, 
Maiya, Shad, Mirbolouk, & Padma Kumar, 2011; Paul Dendale, Patrick Doherty, Dan Gaita, Stefan Höfer, 
Hannah McGee, Miguel Mendes, Josef Niebauer & Massimo F Piepoli, Ugo Corrà, Stamatis 
Adamopoulos, Werner Benzer, Birna Bjarnason-Wehrens, 2014). A recent meta-analysis established 
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there are moderate-sized reductions of depression with CR participation (Rutledge et al., 2013). These 
reductions could be attributed to screening and detection (leading to referral for diagnosis, and where 
positive use of evidence-based therapies such as antidepressants and psychotherapy), social support, 
psychosocial education (e.g., stress management), the mood-enhancing effects of exercise (Samartzis et 
al., 2013), or more likely a combination of these components of CR. Studies also suggest that CR 
participation may attenuate the excess mortality associated with depressive symptoms (C J Lavie, 
Morshedi-Meibodi, & Milani, 2008).  
While depressive symptom reductions are observed in CR trials, in the “real-world”, most CR 
programs have insufficient mental health care capacity to meet required services for many patients 
(Cahill, M.C., Bilanovic, A., Kelly, S., Bacon, S., & Grace, 2015). Where treatment is accessed, patients are 
more often prescribed antidepressants than offered psychotherapy, due again to issues of capacity. 
However, patients prescribed antidepressants are often not monitored, such that therapeutic response 
is not optimized. Moreover, previous research has reported continued use of a class of antidepressants 
known as tricyclics (Grace, Leung, & Stewart, 2008) despite their contraindication in this population, due 
to arrhythmogenic effects (Bradley SM, 2015). Therefore, based on the inconsistency of identification of 
depression among cardiac patients, as well as the poorer health outcomes attributed to depressed 
patients, this thesis will explore many facets of depression screening, treatment, and benefits in cardiac 
patients, including the use of antidepressants in patients assessed for depression during CR, the effects 
of medical history, comorbid conditions, depression status and antidepressant use on the likelihood of 
having major adverse cardiac events, over a 10 year follow-up period. 
L iterature Review 
Cardiovascular Disease and Its Burden 
Cardiovascular diseases (CVDs) are conditions that involve partial or complete blockage of blood vessels 
which can lead to a heart attack or stroke. An estimated 1.6 million Canadians are living with heart 
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disease or the effects of a stroke; 1.3 million Canadians are living with heart disease alone (Hazinski et 
al., 2015). Globally, incidence of CVDs is rising; in 2010, an estimated 111.7 million individuals (1.62% of 
the global population) had angina due to ischemic heart disease, as reported by the Global Burden of 
Disease Study (Turk-Adawi, Sarrafzadegan, & Grace, 2014). Once a patient has CVD, the risk of recurrent 
cardiac events has been estimated at 34.9%, and is even higher in certain groups. For example, in 
cardiac patients with comorbid kidney disease, the risk nearly doubles, to 65.5% (Weiner et al., 2004). 
Depression 
Depression is a mood disorder, characterized by a depressed mood and combination of other 
symptoms such as weight change, sleep disturbance, insomnia, fatigue, feelings of guilt, worthlessness, 
and/or hopelessness. The symptoms may appear in different degrees in individuals, such that they have 
“the blues”. Even mild symptoms can be hazardous in the context of CVD (Vieweg, Hasnain, Lesnefsky, & 
Pandurangi, 2011).  
However, for the diagnosis of depression to be met, according to The American Psychiatric 
Association Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) (APA, 2013) five 
of nine symptoms (examples above) must be present, and at least one of the five must be the cardinal 
features of ‘depressed mood’ or ‘loss of interest or pleasure’. All must be judged to be significant by an 
experienced clinician in terms of severity, duration, abnormality, distress and impairment (i.e., social 
and occupational functioning) during a structured clinical interview for a diagnosis to be made. The ICD-
10 (World Health Organization, 1992) criteria for Major Depressive Disorder (code F33) diagnosis are 
based on a number of characteristics, defined as a disorder characterized by melancholic feelings of 
grief or unhappiness: a melancholy feeling of sadness and despair; a mental condition marked by 
ongoing feelings of sadness, despair, loss of energy, and difficulty dealing with normal daily life; feelings 
of worthlessness and hopelessness, loss of pleasure in activities, changes in eating or sleeping habits, 
and thoughts of death or suicide.  
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Regardless of whether the DSM-V or ICD-10 criteria are used, depression is diagnosed using a semi-
structured interview that determines the length of time mood disturbance was present, the severity of 
the disorder, and whether suicidal ideation is present at the time of assessment (Ceccarini et al., 2014). 
For research purposes, often a validated depressive symptom scale is administered, which has pre-
specified thresholds for probable depression diagnosis; no diagnosis can be made however without a 
structured diagnostic interview by a registered healthcare professional (i.e., clinical psychologist or 
psychiatrist). 
Burden of Depression 
Globally, approximately 20% of CVD patients have depressive symptom levels similar to those 
meeting criteria for Major Depressive Disorder (Thombs et al., 2005). In the general population, rates of 
depression are roughly one-quarter to one-third less prevalent, with estimates around 3-5% (Cohen, 
Edmondson, & Kronish, 2015). Here in Canada, the rates of depression in the general population are 
similar to those globally at 3-5%; in cardiac patients, those rates increase to almost one-third of CVD 
patients (Marzolini, Leung, Alter, Wu, & Grace, 2013).  
Globally, incidence of comorbid depression and CVD are rising, such that the World Health 
Organization (WHO) predict that by the year 2020, both CVD and depression will be the two major 
causes of disability-adjusted life years (Reddy, 2010).  Depression and CVD are so commonly linked, and 
so closely associated with poorer cardiac outcomes, the American Heart Association issued a 2014 
Scientific Statement recommending that depression be elevated to the status of a risk factor in acute 
coronary syndrome survivors (Hazinski et al., 2015). 
Effect of Comorbid Depression in CVD Patients 
Individuals with both CVD and depression have greater functional declines, impaired quality of life, 
and increased morbidity and mortality compared to patients with either CVD or depression alone. An 
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estimated 17.5 million people died from CVDs in 2012, representing 31% of all global deaths (P. M. 
Davidson et al., 2016). In patients with CVD, mortality is twice as high in patients with comorbid 
depression compared to those who do not (van Melle et al., 2008). From an economic standpoint, the 
increased morbidity and mortality cause an increased burden on the health care system, creating an 
increased demand for resources caused by increased visits to emergency departments, decreased bed 
availability, and higher amounts of surgical and pharmacological intervention over the life span of the 
patient (Barth, Härter, Paul, & Bengel, 2005). Therefore, it is important to detect and address depression 
in CVD patients from both a health and economic standpoint. 
Mechanisms Linking Depression and CVD 
Depression and CVDs are linked by both behavioural and biological mechanisms. With regard to the 
former, certain behaviors in depressed patients contribute to the progression of coronary disease. These 
include poor diet, lack of exercise, poor medication adherence, and tobacco use (Huffman et al., 2014). 
Psychosocially, depressed CVD patients have decreased ability to deal with life stressors, and a smaller 
support network (Berkman et al., 2003). This constellation of behavioural and psychological symptoms 
causes an individual to be more likely to display sedentary behavior, poor coping skills, unhealthy 
dietary habits, and decreased ability for tobacco use or alcohol cessation(WHO, 2000). 
On a physiological level, depression is linked to CVD by a number of factors. Compared with 
nondepressed individuals, depressed patients with CVD often have higher levels of biomarkers found to 
predict cardiac events or promote atherosclerosis (Huffman et al., 2016; C J Lavie et al., 2008). Although 
not always consistent, several studies in depressed patients with coronary artery disease have reported 
reduced heart rate variability (suggesting increased sympathetic activity and/or reduced vagal activity), 
evidence of hypothalamic-pituitary-adrenal axis dysfunction, increased plasma platelet factor and alpha-
thromboglobulin (suggesting enhanced platelet activation),impaired vascular function, and increased C-
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reactive protein, interleukin-6, intercellular adhesion molecule-1, and fibrinogen levels (suggesting 
increased innate inflammatory response) (Zhang, 2015).  
Treatment Of Depression In CVD 
The major evidence-based therapies for depression are psychotherapy and antidepressant 
medications. These have been tested and shown efficacious in CVD patients as well. With regard to 
psychotherapy, the most effective form for depression has consistent been cognitive behavioral therapy 
(Berkman et al., 2003; Hare, Toukhsati, Johansson, & Jaarsma, 2014). Cognitive behavioral therapy (CBT) 
is a type of talking therapy (psychotherapy) that assumes that maladaptive thinking patterns cause 
maladaptive behavior and "negative" emotions. Maladaptive behavior, in this context, is behavior that is 
counterproductive or interferes with everyday living. The treatment focuses on changing an individual's 
thoughts (cognitive patterns) in order to change his or her behavior and emotional state (Sniehotta et 
al., 2005). Trials of CBT in CVD patients have shown moderate reductions in depressive symptoms can be 
achieved, as first demonstrated in the ENRICHD trial (Berkman et al., 2003). Other forms of 
psychotherapy have been infrequently tested in CVD patients. A trial of interpersonal psychotherapy 
(IPT) showed no beneficial effect (Lespérance et al., 2007); problem-solving therapy, on the other hand, 
has recently shown considerable promise (K. W. Davidson et al., 2013).  
Furthermore, a large Cochrane review from 2011 focusing on the seminal work on depression 
and cardiac disease has found that though evidence-based treatments are efficacious for depression, 
they may not act to necessarily resolve all of the patients’ change in psychomotor or emotional 
functioning, including deficits in motivation, memory, and cognition. Residual effects from the 
depression may still be present, quality of life increases were inconclusive, and most strikingly, there 
was no improvement with respect to cardiac events and cardiac hospitalizations even in patients with 
the greatest reductions in depressive symptoms (Baumeister, Hutter, & Bengel, 2011). 
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While antidepressant therapy will be considered in more detail below, many patients with 
moderate to severe depression may respond better to the combination of an antidepressant and 
psychotherapy (combination therapy) than to either treatment alone (Hare et al., 2014). In clinical 
practice, the duration and frequency can be customized by the treating therapist to meet the individual 
needs of the patient; some patients may prefer and do well with a less intensive regimen. Moreover, 
many therapeutic trials for depressed CVD patients have been applying stepped, collaborative care 
approaches (K. W. Davidson et al., 2013; Huffman et al., 2014). These treatments have been associated 
with moderately improved depression scores and better cardiac prognosis, though depression 
treatments have not been found to account for all of the increased risk of cardiac events in CVD patients 
(J. H. Lichtman et al., 2014). 
Antidepressants 
 Due to greater accessibility, pharmacotherapy is often the mainstay of the medical management 
of Major Depressive Disorder. Table 1 lists the major classes of antidepressants, along with examples of 
medications in each class, along with clinical recommendations for CVD patients. These are selective 
serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical 
antidepressants, tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). Each are 
described in turn, below. 
In the 1980s, pharmacologic treatment was limited to TCAs and MAOIs; both TCAs and MAOIs 
are referred to as traditional or first-generation antidepressants. These drugs are often accompanied by 
multiple side effects that many patients find intolerable; e.g., TCAs tend to cause anticholinergic effects 
including dry mouth and eyes, urinary hesitancy, and sometimes fluid retention and constipation; MAOIs 
have the potential to produce hypertensive crisis if taken along with certain foods or dietary 
supplements containing excessive amounts of tyramine (MacGillivray et al., 2003). Thus, first-generation 
antidepressants are no longer agents of choice in many circumstances (Stephen Waring, 2010).  
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After the 1980s, newer treatments were developed, including SSRIs, SNRIs, and other second-
generation drugs. The first of the second-generation drugs was introduced to the US market in 1985, 
when bupropion (a so-called “atypical”) was approved for the treatment of major depressive disorders. 
In 1987, the US Food and Drug Administration (FDA) approved the first SSRI, fluoxetine. Since then, five 
other SSRIs have been introduced: sertraline (1991), paroxetine (1992), citalopram (1999), fluvoxamine 
(2000), and escitalopram (2002). The SNRIs were first introduced to the market in 1993 with the 
approval of venlafaxine. Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor 
(SSNRI), was approved for the treatment of major depressive disorder in 2004 (Khawaja, Westermeyer, 
Gajwani, & Feinstein, 2009; Stephen Waring, 2010).  
The mechanism of action of most second-generation antidepressants is poorly understood. In 
general, these drugs work through their effect on prominent neurotransmitters in the central nervous 
system. The SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline) act by 
selectively inhibiting the reuptake of serotonin (5-hydroxy-tryptamine, 5-HT) at the presynaptic 
neuronal membrane. The SNRIs (desvenlafaxine, venlafaxine) are potent inhibitors of serotonin and 
norepinephrine reuptake and weak inhibitors of dopamine reuptake. Mirtazapine, sometimes 
characterized as an SNRI and other times as an atypical, is believed to enhance central noradrenergic 
and serotonergic activity as a 5-HT2 and 5-HT3 receptor antagonist. Bupropion is a relatively weak 
inhibitor of the neuronal uptake of norepinephrine, serotonin, and dopamine. Preclinical studies of 
duloxetine suggest that it is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a 
less potent inhibitor of dopamine reuptake (Knadler, Lobo, Chappell, & Bergstrom, 2011). 
Effects of Antidepressants on Symptom Reduction and Clinical Outcomes in CVD Patients 
There have been 9 major trials of depression treatment in CVD patients; of which 6 administered 
antidepressants.  Each of the later trials is described below, with a particular focus on the effects on 
MACEs including death.  
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In 2007, a Canadian Randomized Clinical Trial titled Cardiac Randomized Evaluation of 
Antidepressant and Therapy Efficacy (CREATE) was conducted via St. Michael’s Hospital in Toronto 
(Lespérance et al., 2007). The study was a randomized, controlled, 12-week, parallel-group trial 
conducted May 1, 2002, to March 20, 2006, among 284 patients with CAD from 9 Canadian academic 
centers. All patients met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria 
for diagnosis of major depression of 4 weeks' duration or longer and had baseline 24-item Hamilton 
Depression Rating Scale (HAM-D) scores of 20 or higher. The study looked at depressed patients with 
coronary artery disease in a 2 x 2 design (that is, Citalopram (SSRI) vs placebo compared to IPT vs 
placebo). The rationale behind using IPT in comparison to CBT as the form of psychotherapy offered was 
that IPT for depression is a form of psychotherapy that focuses on the relationships between a person 
and significant others. It is based on the idea that humans, as social beings, have their personal 
relationships at the center of psychological problems. This aspect of IPT would have addressed the 
realities of living with CAD for the patients involved, and emphasized the contribution of a social 
network to psychosocial components of depression. Also, IPT’s incorporation of social networks would 
have mitigated the effect of social isolation on patients; lack of social support had previously been linked 
to increased morbidity and mortality for patients. The results demonstrated that citalopram was 
superior to placebo in reducing 12-week HAM-D scores (mean difference, 3.3 points; 96.7% confidence 
interval [CI], 0.80-5.85; P = .005), with a small to medium effect size of 0.33. Mean HAM-D response 
(52.8% vs 40.1%; P = .03) and remission rates (35.9% vs 22.5%; P = .01) and the reduction in Beck 
Depression Inventory (BDI-II) scores (difference, 3.6 points; 98.3% CI, 0.58-6.64; P = .005; effect size = 
0.33) also favored citalopram. There was no evidence of a benefit of IPT over clinical management, with 
the mean HAM-D difference favoring clinical management (-2.26 points; 96.7% CI, -4.78 to 0.27; P = .06; 
effect size, 0.23). The difference on the BDI-II did not favor clinical management (1.13 points; 98.3% CI, -
1.90 to 4.16; P = .37; effect size = 0.11). To conclude, the authors found that based on the results, 
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citalopram or sertraline plus clinical management should be considered as a first-step treatment for 
patients with CAD and major depression instead of IPT or other psychosocial skills management 
techniques. 
The Enhancing Recovery in Coronary Heart Disease (ENRICHD) study was a multicenter randomized 
clinical trial of 2,481 post-MI patients (ENRICHD Investigators, 2001). Subjects met criteria DSM-IV 
criteria for major depression, minor depression with history of major depression, or met certain criteria 
on a social support instrument. The primary endpoint was cardiovascular mortality and non-fatal 
recurrent MI. Intervention involved 6 group sessions of cognitive behavioral therapy over 6 months, 
followed by open group membership, with SSRI use also allowed for unremitting or severe depression in 
both groups. The intervention did not increase event-free survival after 29 months (75.8% vs 75.9%).  
Also no differences in mortality or infarction in any of the subgroups (e.g. those isolated and depressed). 
There were, however, significant improvements in depression and social support among intervention 
participants. Though some benefits were seen, lack of benefits across all outcomes may be due to 
improvements in depression and social support that also occurred in the usual care group, as well as 
high SSRI use in both groups. Though the trial demonstrated that a combination of short-term individual 
CBT and a selective serotonin reuptake inhibitor , when needed, was significantly better than usual care 
(referral to a psychologist after a brief screening on-site, followed by antidepressant therapy as 
required) at reducing depressive symptoms over 6 months in depressed or socially isolated myocardial 
infarction patients, the effect size was small. The study ultimately failed to show that the ENRICHD 
treatment protocol was better than usual care in preventing all-cause mortality and recurrent 
myocardial infarctions. A follow-up, post-hoc analysis demonstrated positive changes (per 1 point 
increase) in somatic depressive symptoms (HR: 0.95; 95% CI: 0.92–0.98; p =0.001) but not in cognitive 
depressive symptoms (HR: 0.98; 95% CI: 0.96–1.01; p =0.19) were related to a reduced risk of recurrent 
MI and mortality after adjustment for baseline depression scores. After controlling for demographic and 
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clinical variables, the association between changes in somatic depressive symptoms and event-free 
survival remained significant in the intervention arm (HR: 0.93; 95% CI: 0.88–0.98; p =0.01) only (Roest 
et al., 2013). 
The Sertraline Anti-Depressant Heart Attack Randomized Trial (SADHART) was a randomized 
controlled trial examining pharmacological treatment versus placebo in 369 patients with either 
unstable angina or myocardial infarction and comorbid major depressive disorder (Glassman et al., 
2002).  The trial was double-blind and placebo-controlled, and patients received either sertraline (an 
SSRI) or a placebo for 16 weeks after all patients were given a placebo for the initial two weeks. The 
analysis divided the patients to examine a more severely depressed subgroup with higher Hamilton 
Depression Inventory (HAM-D) scale scores at baseline, and with history of 2 or more recurrent major 
depressive disorder episodes. The primary (safety) outcome measure was change from baseline in left 
ventricular ejection fraction; secondary measures included surrogate cardiac measures and 
cardiovascular adverse events, as well as scores on the HAM-D scale and Clinical Global Impression 
Improvement scale (CGI-I) in the total randomized sample. Among all patients, a repeated-measures 
analysis found sertraline to be significantly superior to placebo on the CGI-I scale measured over 24 
weeks, but not on the HAM-D scale, which was obtained over 16 weeks. In the 2 recurrent depression 
groups, sertraline was significantly superior to placebo on both the CGI and HAM-D measures. In all 
groups, responder status using the standard criteria of CGI-I score of 1 or 2 (very much or much 
improved) was achieved at end point by significantly more patients treated with sertraline than with 
placebo. However, there was no difference between groups on endpoint measure of number of urgent 
cardiac events in the sertraline-treated group versus the placebo group.   
The Myocardial Infarction and Depression Intervention Trial (MIND-IT) was conducted in 2007 as a 
prospective multicenter study, where 2177 MI patients were evaluated for depressive disorder during 
the first year post-MI (Honig et al., 2007). Ninety-one patients who met the DSM-IV criteria for major or 
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minor depressive disorder were randomized to a 24-week, double-blind, placebo-controlled trial.  The 
antidepressant studied in this trial was Mirtazapine, a noradrenergic and specific serotonergic 
antidepressant that is used primarily in the treatment of depression. It is also commonly used as an 
anxiolytic, hypnotic, antiemetic and appetite stimulant. In terms of structure, mirtazapine can also be 
classified as a tetracyclic antidepressant (TeCA), which leads to this drug being classified as either an 
atypical antidepressant as well as, occasionally, a TCA (though it is only structurally-related to the TCA 
family). The primary outcome was reduction in depressive symptomatology on the 17-item Hamilton-
Depression Rating Scale (Ham-D), and secondary outcomes were the BDI-II and depression subscale of 
the Symptom Check List 90 items (dSCL-90) as well as the Clinical Global Impression scale. The trial 
found that, using the “last observation carried forward” method, mirtazapine did not show to be 
superior to placebo on the Ham-D, but did on the BDI, dSCL-90, and CGI scales over the acute treatment 
phase of 8 weeks (n = 91). Using mixed models analysis over the entire 24 weeks of treatment (n = 40), 
they found a significant difference favoring mirtazapine to placebo on the Ham-D, BDI, and CGI, but on 
the dSCL-90, this difference was not significant. In conclusion, the authors demonstrated efficacy of 
mirtazapine on primary and secondary depression measures, and established that mirtazapine seems to 
be safe in the treatment of post-MI depression. 
The Montreal Heart Attack Readjustment Trial (M-HART) was a randomised, controlled trial to 
assess whether psychological distress screening-related improvement in cardiac prognosis for men and 
women recovering from MI, as reported in previous literature, could be replicated using a screening 
program (Frasure-Smith, 1995). This study examined whether the program would reduce 1-year cardiac 
mortality for women and men. This trial consisted of 1376 post-MI patients (903 men, 473 women) 
assigned to the intervention program (n=692) or usual care (n=684) for 1 year. All patients completed a 
baseline interview that included assessment of depression and anxiety. Survivors were also interviewed 
at 1 year. Unfortunately, the program had no overall survival impact. Preplanned analyses showed 
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higher cardiac (9·4 vs 5·0%, p=0·064) and all-cause mortality (10·3 vs 5·4%, p=0·051) among women in 
the intervention group. There was no evidence of either benefit or harm among men (cardiac mortality 
2·4 vs 2·5%, p=0·94; all-cause mortality 3·1 vs 3·1%, p=0·93). Therefore, the program's impact on 
depression and anxiety among survivors was small. The authors concluded that the results do not 
warrant the routine implementation of programs that involve psychological-distress screening and home 
nursing intervention for patients recovering from MI. The poorer overall outcome for women, and the 
possible harmful impact of the intervention on women, underline the need for further research and the 
inclusion of adequate numbers of women in future post-MI trials. Women are usually underserved in 
the CR community as there have been barriers to access to care; women are more likely to feel 
responsible for continuing to support their family members, even though they require individualized 
treatment. They are also less likely to adopt a “goal-driven” attitude towards fitness and lifestyle goals 
emphasized during CR, which may end up favoring outcomes for men instead of women. 
In 2013, the Centralized, Stepped, Patient Preference–Based Treatment for Patients With Post–
Acute Coronary Syndrome Depression (CODIACS) trial was published (K. W. Davidson et al., 2013),  to 
provide evidence regarding conflicting reports concerning whether depression can be successfully 
managed after acute coronary syndrome (ACS) and whether it can be cost-effective. The trial design was 
a multicenter randomized controlled trial; patients were recruited from 2 private and 5 academic 
ambulatory centers across the United States. A total of 150 patients with elevated depressive symptoms 
(Beck Depression Inventory [BDI] score ≥10) 2 to 6 months after an ACS, recruited between March 18, 
2010, and January 9, 2012. Patients were randomized to 6 months of centralized depression care 
(patient preference for problem-solving treatment given via telephone or the Internet, 
pharmacotherapy, both, or neither), stepped every 6 to 8 weeks (active treatment group; n = 73), or to 
locally determined depression care after physician notification about the patient's depressive symptoms 
(usual care group; n = 77). The change in depressive symptoms during 6 months and total health care 
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costs were evaluated, and the results determined that depressive symptoms decreased significantly 
more in the active treatment group than in the usual care group (differential change between groups, 
−3.5 BDI points; 95% CI, −6.1 to −0.7; P = .01). Although mental health care estimated costs were higher 
for active treatment than for usual care, overall health care estimated costs were not significantly 
different (difference adjusting for confounding, −$325; 95% CI, −$2639 to $1989; P = .78). The authors 
concluded that for patients with post-ACS depression, active treatment had a substantial beneficial 
effect on depressive symptoms and that this kind of depression care is feasible, effective, and may be 
cost-neutral within 6 months. 
In 2010, the Coronary Psychosocial Evaluation Studies Randomized Controlled Trial (COPES) was 
launched to examine depressed patients with acute coronary syndrome (ACS) (defined as stable or 
unstable angina, urgent hospitalizations and revascularization) and their satisfaction levels with 
depression care (K. W. Davidson et al., 2010). A 3-month observation period to identify patients with 
ACS and persistent depressive symptoms was followed by a 6-month randomized controlled trial. From 
January 1, 2005, through February 29, 2008, 237 patients with ACS from 5 hospitals were enrolled, 
including 157 persistently depressed patients randomized to intervention (initial patient preference for 
problem-solving therapy and/or pharmacotherapy, then a stepped-care approach involving 80 patients) 
or usual care (77 patients) and 80 non-depressed patients who underwent observational evaluation, as a 
secondary control to the usual care group. The primary outcome was patient satisfaction with 
depression care. Secondary outcomes were depressive symptom changes (assessed with the Beck 
Depression Inventory), major adverse cardiac events, and death. At the end of the trial, the proportion 
of patients who were satisfied with their depression care was higher in the intervention group (54% of 
80) than in the usual care group (19% of 77) (odds ratio, 5.4; 95% confidence interval [CI], 2.2-12.9 [P < 
.001]). The Beck Depression Inventory score decreased significantly more (t(155) = 2.85 [P = .005]) for 
intervention patients (change, -5.7; 95% CI, -7.6 to -3.8; df = 155) than for usual care patients (change, -
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1.9; 95% CI, -3.8 to -0.1; df = 155); and the depression effect size was 0.59 of the standard deviation. At 
the end of the trial, 3 intervention patients and 10 usual care patients had experienced major adverse 
cardiac events (MACEs) (4% and 13%, respectively; [P = .047]), as well as 5 nondepressed patients (6%) 
for the intervention vs nondepressed cohort, [P = .49]). The authors concluded that improved 
depression care for patients with ACS was associated with greater satisfaction, a greater reduction in 
depressive symptoms, and an encouraging improvement in prognosis. 
Another Randomized Controlled Trial (RCT), a study design which randomizes patients to either 
usual care (or placebo) compared to a treatment group without the participants knowing which group to 
which they belong, to look at psychosocial intervention in the management of secondary cardiovascular 
disease was titled The Secondary Prevention in Uppsala Primary Health Care Project (SUPRIM) 
(Gulliksson et al., 2007).  The aim was to look at cognitive behavioural therapy and measure its effects 
on cardiovascular disease recurrence, given that psychosocial factors are independently associated with 
increased risk of cardiovascular disease. The study included 362 women and men (75 years or younger) 
who were discharged from the hospital after a coronary heart disease event within the past year. 
Patients were randomized to receive traditional care (reference group, 170 patients) or traditional care 
plus a CBT program (intervention group, 192 patients), focusing on stress management, with 20 two-
hour sessions during 1 year. Median attendance at each CBT session was 85%. Outcome variables were 
all-cause mortality, hospital admission for recurrent CVD, and recurrent acute myocardial infarction. 
During a mean 94 months of follow-up, the intervention group had a 41% lower rate of fatal and 
nonfatal first recurrent CVD events (hazard ratio [95% confidence interval], 0.59 [0.42-0.83]; P = .002), 
45% fewer recurrent acute myocardial infarctions (0.55 [0.36-0.85]; P = .007), and a nonsignificant 28% 
lower all-cause mortality (0.72 [0.40-1.30]; P = .28) than the reference group after adjustment for other 
outcome-affecting variables. In the CBT group there was a strong dose-response effect between 
intervention group attendance and outcome. During the first 2 years of follow-up, there were no 
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significant group differences in traditional risk factors. The investigators concluded that CBT intervention 
decreases the risk of recurrent CVD and recurrent acute myocardial infarction, which may have 
implications for secondary preventive programs in patients with coronary heart disease.  
A recent RCT, The Management of Sadness and Anxiety in Cardiology (MOSAIC) Randomized Clinical 
Trial (MOSAIC) was published in 2014, looking at interventions for depression and anxiety associated 
with adverse cardiovascular outcomes in patients with recent acute cardiac events, given that there has 
been minimal study of collaborative care management models for mental health disorders in high-risk 
cardiac inpatients, and none have simultaneously managed depression and anxiety disorders (Huffman 
et al., 2014). This study aimed at determining the impact of a low-intensity CC intervention for 
depression, generalized anxiety disorder, and panic disorder among patients hospitalized for an acute 
cardiac illness. The design was a single-blind randomized clinical trial, with study assessors blind to 
group assignment, from September 2010 through July 2013 of 183 patients admitted to inpatient 
cardiac units in an urban academic general hospital for acute coronary syndrome, arrhythmia, or heart 
failure and found to have clinical depression, generalized anxiety disorder, or panic disorder on 
structured assessment. Participants were randomized to 24 weeks of a low-intensity telephone-based 
multicomponent CC intervention targeting depression and anxiety disorders (n = 92) or to enhanced 
usual care (serial notification of primary medical providers; n = 91). The CC intervention used a social 
work care manager to coordinate assessment and stepped care of psychiatric conditions and to provide 
support and therapeutic interventions as appropriate. The primary outcome measure was improvement 
in mental health–related quality of life (Short Form-12 Mental Component Score [SF-12 MCS]) at 24 
weeks, compared between groups using a random-effects model in an intent-to-treat analysis. Patients 
randomized to CC had significantly greater estimated mean improvements in SF-12 MCS at 24 weeks 
(11.21 points [from 34.21 to 45.42] in the CC group vs 5.53 points [from 36.30 to 41.83] in the control 
group; estimated mean difference, 5.68 points [95% CI, 2.14-9.22]; P = .002; effect size, 0.61). Patients 
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receiving CC also had significant improvements in depressive symptoms and general functioning, and 
higher rates of treatment of a mental health disorder; anxiety scores, rates of disorder response, and 
adherence did not differ between groups. The study evaluated the use of a CC model and found that 
their telephone-based, low-intensity model to concurrently manage cardiac patients with depression 
and/or anxiety disorders was effective for improving mental health–related quality of life in a 24-week 
trial. 
All of the studies summarized above give a wealth of information concerning depression in the CVD 
community: that all-inclusive screening, while effective, may not be worth the added cost and time 
required to screen every patient; that antidepressants are usually found to be more effective than either 
placebo or usual care, and that finally, though both antidepressants and psychosocial therapy (usually 
CBT) have been found to decrease depression and improve secondary outcomes and relapse events, it 
remains to be seen how much of an effect is conferred by the treatment, and how much either 
spontaneously resolves as the patient feels better, or how much benefit is conferred by attending a CR 
program model, which includes exercise as a core component. 
Observational Data on the Effects of Antidepressant Use in CVD Patients – Morbidity and Mortality 
As seen above, effects of psychosocial interventions on depression symptoms in patients with CVD 
have been modest and prone to confounding effects- furthermore, effects on morbidity and mortality 
have only been explored in recent trials. A meta-analysis of 36 studies involving 12,851 patients showed 
only a slight reduction in non-fatal MI and no reduction in cardiac mortality; however, many studies 
often had a negligible improvement in depression  (Anderson & Taylor, 2014). However, in the CR 
setting, a meta-analysis of 23 randomized trials showed all-cause mortality to be 28% lower in those 
trials that included psychosocial interventions compared to those who did not (van Melle et al., 2008), 
but reduction in mortality seen only in those who effectively reduced psychological distress. Many of the 
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studies looking at mortality and morbidity rates in cardiac patients on antidepressants have been 
observational in nature; these are described in turn, below: 
In 2014, researchers looked at antidepressants, autonomic function, and mortality in patients with 
coronary heart disease (Zimmermann-Viehoff, Kuehl, Danker-Hopfe, Whooley, & Otte, 2014). The data 
used was from a larger study titled the Heart & Soul Study. This study aimed to examine whether the 
use of TCAs or SSRIs was associated with mortality in patients with coronary heart disease, and to 
determine whether this association is mediated by autonomic function. A total of 956 patients with 
coronary heart disease were followed for a mean duration of 7.2 years. Autonomic function was 
assessed as heart rate variability, and plasma and 24-h urinary norepinephrine. Of 956 patients, 44 
(4.6%) used TCAs, 89 (9.3%) used SSRI, and 823 (86.1%) did not use antidepressants. At baseline, TCA 
users exhibited lower heart rate variability and higher norepinephrine levels compared with SSRI users 
and antidepressant non-users. At the end of the observational period, 52.3% of the TCA users had died 
compared with 38.2% in the SSRI group and 37.3% in the control group. The adjusted hazard ratio (HR) 
for TCA use compared with non-use was 1.74 [95% confidence interval (CI) 1.12-2.69, p = 0.01]. Further 
adjustment for measures of autonomic function reduced the association between TCA use and mortality 
(HR = 1.27, 95% CI 0.67-2.43, p = 0.47). SSRI use was not associated with mortality (HR = 1.15, 95% CI 
0.81-1.64, p = 0.44). The authors concluded that the use of TCA was associated with increased mortality. 
This association was at least partially mediated by differences in autonomic function; however, the 
findings suggest that TCAs should be avoided in patients with coronary heart disease. 
In 2011, The Danish Heart Failure Clinics Network funded a study to look at whether 
pharmacologically treated depression was associated with increased mortality risk in systolic heart 
failure patients (O’Connor et al., 2010). Patients (n=3346) with systolic heart failure (left ventricular 
ejection fraction≤0.45) and primarily New York Heart Association (NYHA) classes II–III (78%) were 
recruited from a clinical database used in 20 heart failure clinics in Denmark. The association between 
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pharmacologically treated depression identified by at least one prescription of an antidepressant and 
mortality risk was evaluated. Follow-up time was 540 days (range: 30–1600 days), and 539 patients died 
over the time span. For 243 patients (7%) an antidepressant had been prescribed at least once. In a Cox 
Proportional Hazard Model, pharmacologically treated depression was associated with a 49% increased 
mortality risk (Hazard ratio: 1.49, 95% confidence interval: 1.03–2.16) after adjustment for traditional 
confounders. Three months after the baseline visit in the heart failure clinic, these patients received 
lower doses of beta-blockers than patients without antidepressant therapy (p=0.006). Female sex 
(p<0.001) and NYHA classes III–IV (p=0.007) were associated with the prescription of an antidepressant. 
Their results suggest that pharmacologically treated depression is associated with a 49% increased 
mortality risk, and that these high-risk patients receive lower doses of beta-blockers than patients with 
no antidepressant therapy. 
Another study, from 2013, looked at whether depression and the use of antidepressants were 
related to long-term mortality in heart failure (Diez-Quevedo et al., 2013). Heart failure outpatients 
(n=1017) from a specialized tertiary unit in Spain were studied for a median follow-up of 5.4 years. 
Depressive symptoms were assessed using an abbreviated version of the geriatric depression scale. 
Survival rates during the study period (August 2001 until December 2010) and hazard ratios (HR) for 
mortality were adjusted by several demographic and clinical variables. Depressive symptoms were 
detected in 302 patients (29.7%) at baseline and 222 (21.8%) during follow-up; 304 patients (29.9%) 
received at least one prescription of antidepressants, mainly selective serotonin reuptake inhibitors 
(92.8%); 441 patients (43.4%) died. In a multivariate Cox proportional hazard model, depression was 
associated with an increased all-cause (HR, 1.39; 95% CI, 1.15-1.68), but not cardiovascular, mortality 
risk after adjustment for several demographic and clinical confounders. The use of any antidepressant 
was not independently associated with mortality (HR, 0.89; 95% CI, 0.71-1.13), but benzodiazepines 
showed a protective role (HR, 0.70; 95% CI, 0.57-0.87). On the contrary, fluoxetine prescriptions, but not 
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duration of fluoxetine treatment, were associated with increased mortality (HR, 1.66; 95% CI, 1.13-2.44). 
The authors concluded that depressive symptoms are associated with long-term mortality, but the use 
of antidepressants and benzodiazepines is safe regarding survival in HF patients, although further 
research is needed considering individual antidepressants separately. 
Another study used data from the SADHART (Sertraline Against Depression and Heart Disease in 
Chronic Heart Failure) trial mentioned above. Researchers tested the hypothesis that heart failure 
patients treated with sertraline would have lower depression scores and fewer cardiovascular events 
compared with placebo, given that depression is common among heart failure patients and is associated 
with increased hospitalization and mortality (Glassman et al., 2002). The SADHART trial was a 
randomized, double-blind, placebo-controlled trial of sertraline 50 to 200 mg/day versus matching 
placebo for 12 weeks. All participants also received nurse-facilitated support. Eligible patients were age 
45 years or older with HF (left ventricular ejection fraction ≤45%, New York Heart Association functional 
class II to IV) and clinical depression (Diagnostic and Statistical Manual of Mental Disorders-Fourth 
Edition criteria for current major depressive disorder). Primary end points were change in depression 
severity (Hamilton Depression Rating Scale total score) and composite cardiovascular status at 12 
weeks. A total of 469 patients were randomized (n = 234 sertraline, n = 235 placebo). The mean ± SE 
change from baseline to 12 weeks in the Hamilton Depression Rating Scale total score was −7.1 ± 0.5 
(sertraline) and −6.8 ± 0.5 (placebo) (p < 0.001 from baseline, p = 0.89 between groups, mean change 
between groups −0.4; 95% confidence interval: −1.7 to 0.92). The proportions whose composite 
cardiovascular score worsened, improved, or was unchanged were 29.9%, 40.6%, and 29.5%, 
respectively, in the sertraline group and 31.1%, 43.8%, and 25.1%, respectively, in the placebo group (p 
= 0.78). The authors concluded that sertraline was safe in patients with significant HF. However, 
treatment with sertraline compared with placebo did not provide greater reduction in depression or 
improved cardiovascular status among patients with HF and depression. 
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The final study that will be examined regarding antidepressant use and cardiovascular-related 
morbidity and mortality is one completed in 2009, predicated on the literature that indicated treatment 
with antidepressants may improve survival in cardiac patients (Fosbol et al., 2009). Guidelines 
recommend use of SSRIs; but knowledge of the prognostic effect of different classes of antidepressants 
is sparse. The authors studied 99,335 patients surviving first hospitalization for heart failure from 1997 
to 2005. Use of medication and antidepressants (divided into tricyclic antidepressants (TCA) and SSRI) 
was determined by prescription claims. Risk of overall and cardiovascular death associated with 
antidepressants, heart failure medication and co-administration of these two drug-classes was 
estimated by Cox proportional hazard analyses. Propensity adjusted models were performed as 
sensitivity analysis. In the study period there were 53,988 deaths of which 83.0% were from 
cardiovascular causes (median follow-up 1.9 years). Use of beta-blockers was associated with decreased 
risk of cardiovascular death (hazard ratio (HR)=0.77, 95% confidence interval (CI): 0.75-0.79). 
Antidepressants were prescribed to 19,411 patients, and both TCA and SSRI were associated with 
increased risk of overall and cardiovascular death (TCA: HR=1.33, CI: 1.26-1.40 and HR=1.25, CI: 1.17-
1.32 and SSRI: HR=1.37, CI: 1.34-1.40 and HR=1.34, CI: 1.30-1.38, respectively). Co-administration of SSRI 
and beta-blockers was associated with a higher risk of overall and cardiovascular death compared with 
co-administration of beta-blockers and TCA (p for interaction <0.01). The authors concluded that use of 
antidepressants in patients with heart failure was associated with worse prognosis. Co-administration of 
SSRIs and beta-blockers was associated with increased risk of overall death and cardiovascular death 
compared with co-administration of TCAs and beta-blockers. To further clarify the interaction of SSRIs 
and beta-blockers (beta-blockers being commonly used in HF patients), clinical trials testing the optimal 
antidepressant strategy in HF patients are warranted. Though TCAs are contraindicated, there may be 
certain cases, such as with co-administration of beta-blockers, where TCA implementation may be 
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beneficial. However, this is currently based on limited evidence and would require much more testing 
before implementation could be undertaken. 
Each of these studies has examined the effects of taking antidepressants on future MACEs. None of 
the studies have found the antidepressant treatments to be completely effective regarding MACE 
prevention; however, the utility of antidepressants is limited due to individual and environmental 
factors which may affect how well the antidepressant is working, as well as the side effect profile on an 
individual level. For patients for whom the antidepressants worked, certain studies seem to indicate that 
there is no reduction in morbidity and mortality compared to antidepressant non-users (Glassman et al., 
2002; O’Connor et al., 2010); still other studies show that antidepressants have a relatively small 
advantage over non-use (Zimmermann-Viehoff et al., 2014); and finally, that certain classes of 
antidepressants may be associated with increased cardiac events (Fosbol et al., 2009). TCAs have been 
repeatedly shown to be cardiotoxic (Fosbol et al., 2009; Stephen Waring, 2010); however, co-
administration with beta-blockers seems to decrease their lethality, as demonstrated in the 2009 study 
by Fosbol et al. At this point, antidepressants seem to generally be safe for cardiac patients, and this is 
true only for the SSRIs, as none of the other classes have been tested adequately, and TCAs may actually 
be harmful and thus, are contraindicated in this population. Interestingly, though SSRIs have been 
demonstrated to be relatively safe in cardiovascular patients, fluoxetine in particular has been 
associated with worse outcomes compared to other SSRIs (Diez-Quevedo et al., 2013). Future research 
is needed to further examine the major classes of antidepressants, as well as look at antidepressants 
individually for their effects on mortality and morbidity in cardiac populations. 
Since guidelines for depression treatment in CVD patients have been created by many organizations, 
certain meta-analyses have recently been undertaken to determine if the guidelines can be improved, 
and what recommendations should be made, given the current body of literature on the subject. A large 
meta-analysis in 2013 completed by Thombs, et al., looked at whether or not the current American 
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Heart Association’s guidelines for mandatory depression screening in cardiac patients should be revised 
in light of conflicting research. Depression treatment with antidepressants or psychotherapy generated 
modest symptom reductions among post-myocardial infarction (post-MI) and stable CHD patients (N = 6; 
effect size = 0.20–0.38), but antidepressants did not improve symptoms more than placebo in 2 heart 
failure trials (Diez-Quevedo et al., 2013; Taylor & Frasure-Smith, 1995). Depression treatment did not 
improve cardiac outcomes. The conclusion was that, given the modest evidence for non-heart failure 
cardiac patients, depression treatment only improved outcomes modestly; in heart failure patients, this 
benefit was negated. Since effects of treating depression are so small, the recommendation was that the 
American Heart Association’s guidelines should be changed to reflect current literature, and the lack of 
evidence regarding the subject of depression screening (Thombs et al., 2013). 
Another meta-analysis from 2013 performed by Rutledge, et al. , attempted to quantify the efficacy 
of mental health treatments- both pharmacological and psychotherapeutic- and cardiac rehabilitation 
treatments for improving event risk and depression in patients with coronary heart disease  . The 
authors found that among patients with CVD, mental health treatments and CR may each reduce 
depression and CVD events, but only CR is effective in reducing total mortality. The results support a 
continued role for mental health treatments and a larger role for mental health professionals in CR. 
As shown in both observational trials and meta-analyses, the research on antidepressant use and its 
utility in reducing excess mortality in depressed cardiac patients has shown modest benefit. 
Exacerbating the issue is that trials are often underpowered; observational studies looking at morbidity 
and mortality in depressed cardiovascular patients are often secondary analyses, and hence limited. 
Differences in antidepressants and classes may affect morbidity and mortality; however, the effects 
have been indistinguishable through current data. The randomized, controlled trials have, as yet, not 
focused entirely on cardiac events and mortality, and the observational data seems to indicate that 
antidepressant use can be associated with higher depression and increased incidence of MACEs.   
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Antidepressant Treatment Recommendations In CVD Patients 
Data on the use of antidepressants in patients with coronary heart disease are limited. With 
regard to choice of agent, SSRIs are the recommended class in CVD. The SSRIS sertraline and citalopram 
specifically are the first-line antidepressant drugs for patients with CVD.  They are generally well-
tolerated, effective and safe to use in patients with CHD when appropriate precautions are taken. 
Sertraline is safe post-MI and considered the drug of choice in these patients. Citalopram is associated 
with dose-dependent QT interval prolongation and is contra-indicated in patients with known QT 
interval prolongation. It is also cautioned in patients at higher risk of developing Torsades de Pointes 
(Lichtman et al., 2008).  
SNRIs, due to being understudied in CVD patients, are not recommended as first-line therapy; 
however, their use is not necessarily contraindicated. Research suggests using SNRIs with caution, and 
that monitoring and follow-up are required for cardiac patients on this class of medications (Khawaja et 
al., 2009; Roest et al., 2013). 
TCAs are best avoided in patients with CHD and are contraindicated in patients who have had a 
recent MI. TCAs are viewed as highly cardiotoxic in overdose and may therefore worsen outcome in CHD 
patients. Mirtazapine (an SNRI) is a suitable alternative in CHD if SSRIs cannot be used but it should be 
used with caution. There is evidence of safety post-MI (Stephen Waring, 2010; Taylor & Frasure-Smith, 
1995).  
Patients with recurrent depression who previously tolerated and responded well to another 
antidepressant may resume taking that agent instead, unless it is now contraindicated. For example, 
TCAs and MAOIs are contraindicated for many patients with heart disease because of their cardiotoxic 
side effects (Waring, 2010).  
Antidepressant Initiation and Monitoring 
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When pharmacological treatment is initiated, patients should be observed closely for the first 2 
months and regularly thereafter to monitor suicidal risk, ensure medication compliance, and detect and 
manage adverse effects. Approximately 15% to 25% of patients stop their antidepressants during the 
first 6 months of treatment because of adverse effects or lack of efficacy (Grace et al., 2008; Khawaja, 
Westermeyer, Gajwani, & Feinstein, 2009). 
Initially, a starting dose should be prescribed and titrated, where necessary, up to the 
recognised minimum effective dose. SSRIs, mirtazapine and venlafaxine (SNRI), and atypicals 
moclobemide and reboxetine are often effective at the starting dose and titration may be unnecessary. 
Lower starting doses should be considered for patients with CVD. General principles in cardiac disease 
are that polypharmacy should be avoided where possible, particularly with drugs likely to affect cardiac 
rate and electrolyte balance, to be aware of QT prolongation is and to be careful with drugs likely to 
increase QT interval; to avoid drugs that are specifically contraindicated, and finally, to avoid rapid 
escalation while monitoring the patient closely (Zemrak & Kenna, 2008). 
Although antidepressant use has been associated with both increased and decreased cardiac 
risk in some epidemiological studies, randomized clinical trials have demonstrated that 2 selective 
serotonin reuptake inhibitor antidepressants, sertraline and citalopram, are safe for patients with CVD 
and effective for reducing moderate, severe, or recurrent depression (Glassman et al., 2002; Honig et 
al., 2007; Lespérance et al., 2007; Samartzis et al., 2013). Nonrandomized, post-hoc analysis of the 
Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) study revealed that patients treated 
with an SSRI, whether assigned to receive cognitive behavioral therapy or usual care, had a 42% 
reduction in death or recurrent MI as compared with the depressed patients not receiving an 
antidepressant (Roest et al., 2013). Given that SSRI treatment soon after acute MI appears safe, is 
relatively inexpensive, and may be effective for post-acute-MI depression, it may be a viable option for 
these patients. Not only does treatment improve mood and quality of life, but studies have shown that 
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depression interferes with compliance, and treatment of depressive symptoms may improve medication 
adherence in patients after acute MI (Khawaja et al., 2009).  
Sertraline and citalopram are the first-line recommended antidepressant drugs for patients with 
cardiovascular disease. Patients with recurrent depression who previously tolerated and responded well 
to another antidepressant may resume taking that agent instead, unless it is now contraindicated. For 
example, TCAs and MAOIs are contraindicated for many patients with heart disease because of their 
cardiotoxic side effects (Waring, 2010).  
If pharmacological treatment is initiated, patients should be observed closely for the first 2 
months and regularly thereafter to monitor suicidal risk, ensure medication compliance, and detect and 
manage adverse effects. Approximately 15% to 25% of patients stop their antidepressants during the 
first 6 months of treatment because of adverse effects or lack of efficacy (Go et al., 2013; Judith H 
Lichtman et al., 2008). Therefore, potential drug interactions or adverse effects should be closely 
monitored. 
Many anti-depressants have poor adherence rates due to adverse effects. Though side-effect 
profiles vary from class to class of antidepressants, in general, weight gain, tiredness, poor 
concentration and decreased sexual function are main reasons why patients discontinue their 
medications, often without the advice of their doctor (Vanderkooy, Kennedy, & Bagby, 2002).  
Depressive symptom reduction should be assessed after antidepressant initiation. Non-response 
at two to six weeks is a good predictor of overall non-response to a specific agent. If patients do not 
respond, a new agent may be tried. When switching antidepressants, a different SSRI or a better 
tolerated newer-generation antidepressant should be tried, followed if necessary by a trial of an 
antidepressant from a different class (Czarny et al., 2011; Stephen Waring, 2010).  
When changing from one antidepressant to another, consideration should be given to the 
possibility of discontinuation reactions, potential loss of antidepressant effect, and the risks of 
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concomitant therapy. Cross-tapering is one method of switching, whereby the dose of the ineffective or 
poorly-tolerated medicine is slowly reduced while the new medicine is slowly introduced. Sometimes, 
cross-tapering is not necessary or advisable. Concomitant use of some antidepressants is 
contraindicated and a drug-free interval may be required after cessation to avoid clinically significant 
interactions (Czarny et al., 2011; Stephen Waring, 2010; Yekehtaz, Farokhnia, & Akhondzadeh, 2013). 
Potential interactions with the SSRIs should be taken into account when prescribing in CHD. 
Recommendations are for people with depression who also have a chronic physical health problem to 
consider using sertraline as this has a lower propensity for interactions. Venlafaxine, an SNRI, is 
contraindicated in patients with an identified high risk of a serious cardiac ventricular arrhythmia or with 
uncontrolled hypertension. It should be used with caution in established cardiac disease that may 
increase the risk of ventricular arrhythmias (e.g. recent MI). Venlafaxine is associated with a greater risk 
of death from overdose compared with other equally effective antidepressants (Waring, 2010).  
Patients can be on antidepressants for long periods of time. Certain schools of thought indicate 
that as long as the patient has no trouble continuing the medication, and there are no adverse health 
effects due to the drug, that patients may be on antidepressants indefinitely (Czarny et al., 2011; K. W. 
Davidson et al., 2006; Zemrak & Kenna, 2008). Alternately, certain providers ascribe to the view that 
patients should be discontinued from antidepressants after no more than a few years of treatment, 
though this view is in the minority. Patients may be switched from one antidepressant to another due to 
side effects or improved efficacy, or antidepressants may be discontinued all together. When 
discontinuing an antidepressant, there is usually a taper period of 2-4 weeks; the dose is initially given at 
half strength for the first half of the taper, and then at quarter strength for the remainder of the taper 
period. If another antidepressant is to be initiated, preferred technique is to taper off of the first 
medication and taper on to the second. However, some clinicians will, in cases of severe depression, 
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abruptly discontinue the first medication and start the new one, though this method is not preferred 
(MacGillivray et al., 2003).  
 
Rates of Use of Antidepressants in CVD Patients 
A 2011 meta-analysis on rates of use of antidepressants was published by Czarny, et al., whose 
objective was to assess rates of antidepressant use or prescription to patients within a year of an acute 
coronary syndrome or cardiac hospitalization (Czarny et al., 2011). PubMed, PsycINFO, and CINAHL 
databases were searched; a total of 24 articles were included. The majority were from North America 
and Europe, and most utilized chart review or self-report to assess antidepressant use or prescription. 
Although there was substantial heterogeneity in results, overall rates of antidepressant use or 
prescription increased from less than 5% prior to 1995 to 10–15% after 2000. In general, studies from 
North America reported substantially higher rates than studies from Europe, approximately 5% higher 
among studies that used chart or self-report data. The authors concluded that antidepressant use or 
prescription has increased considerably, and that by 2005 approximately 10% to 15% of ACS patients 
were prescribed or using one of these drugs (Czarny et al., 2011).   
Slightly lower values were found in an earlier, population-based study cross-sectional time series 
analysis in which antidepressant prescription data were obtained for elderly Ontarians from 1993 to 
2002 who had experienced an MI, as well as for controls with no history of MI (Benazon, N. , Mamdani, 
M., Coyne, J., 2005). Since there had been a substantial increase in the prescribing of antidepressants on 
a population basis and in particular serotonin reuptake inhibitors (SSRIs), the authors examined how the 
prescribing of antidepressants to patients post–myocardial infarction (MI) changed in the decade 1993 
to 2002, including the proportion accounted for by TCAs. Results were found that indicated that post-MI 
patients were more likely to receive an antidepressant relative to controls, with an overall odds ratio 
(OR) of 1.34; 95% confidence interval (CI), 1.29–1.38. However, with adjustment for the number of 
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medications received, post-MI patients were 20% less likely to receive an antidepressant relative to 
controls, adjusted OR = 0.81; 95% CI, 0.78–0.84. The proportion of antidepressants prescribed to post-
MI patients accounted for by TCAs decreased, but the proportion of post-MI patients receiving a TCA 
remained stable at approximately 6%. In general, the conclusion states that increases in the prescription 
of antidepressants, and in particular SSRIs, to post-MI patients reflect general population trends- rather 
than being specifically due to treating post-MI depression. 
Screening and Diagnosis of Depression in CVD Patients 
 Given the risks associated with depression in the context of CVD, screening is important, so 
depression can be identified and diagnosed. Screening refers to a strategy used in a population to 
identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or 
symptoms. Diagnosis refers to the process of identifying the cause or disease process that matches the 
patient’s symptoms. Screening for depression may aid in identification of depression, which can be 
difficult in those who have CVD, due to the CVD itself causing some cardinal depressive symptoms (e.g., 
sleep disturbance, social role impairment related to hospitalizations) (Gilbody, Sheldon, & House, 2008).  
Several professional associations have published recommendations regarding depression 
screening in cardiac (or chronic disease) patients. Table 2 lists the main associations and their screening 
recommendations, with associated screening tool where screening is indeed recommended. Arguably, 
the most influential guidelines appear to be those issued by the American Heart Association. As shown, 
recommendations for screening (or for instrument, as discussed below) are not consistent (P. Tully, 
2015).  Indeed, some have suggested that there is no evidence to support screening in the context of 
CVD (Thombs et al., 2013; Ziegelstein, Thombs, Coyne, & de Jonge, 2009). Currently, research is 
underway to determine whether the screening in accordance with the AHA protocol is related to 
justifiably improved prognosis for those patients whose depression is identified and treated (K. W. 
Davidson, 2015).  
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With regard to recommended screening tool, the Patient Health Questionnaire-9 (PHQ-9) is now 
commonly accepted as the most sensitive and specific of all of the brief depression screeners (Hazinski 
et al., 2015; Smith et al., 2011). In the clinical setting, tools are required to be brief so that they can be 
easily administered by clinicians, easily scored, and are not too time-consuming. Clinicians often do not 
have a lot of time with their patients, especially in the primary care setting, and so the brevity of the 
screening tool is essential to whether the clinician would be more likely to administer it. Other screening 
tools, such as the Beck Depression Inventory (BDI) are associated with high sensitivity but slightly lower 
specificity (Kourkoveli et al., 2015). Other tests, such as the older PRIME-MD (the precursor to the PHQ), 
the Hamilton Depression Inventory (HAM-D), and Cognitive Behavioural Assessment Hospital Form 
(CBA-H), are no longer commonly-used, and the HADS (Hospital Anxiety and Depression Scale) is 
currently not recommended as an accurate screening tool (Ceccarini et al., 2014; Hare et al., 2014; P. J. 
Tully et al., 2015).  
Indeed, the PHQ is considered one of the most reliable screening tools for depression, based on 
both sensitivity and specificity. The Patient Health Questionnaire (PHQ-2) (Ceccarini et al., 2014; Kurt 
Kroenke, Spitzer, & Williams, 2003) should first be administered (Appendix A, items 1-2). If the answer is 
“yes” to either or both questions, it is recommended that all 9 PHQ items (Appendix A, all items) be 
asked (K Kroenke et al., 2001).  
The PHQ-9 is a brief depression screening instrument (Appendix).Most patients are able to 
complete it without assistance in 5 minutes or less. It yields both a provisional depression diagnosis (i.e., 
structured clinical interview required for formal diagnosis) and a severity score that can be used for 
treatment response monitoring. The PHQ-9 has been shown to have reasonable sensitivity and 
specificity for patients with CHD- PHQ-9 score ≥10 has a sensitivity of 88% and a specificity of 88% for 
major depression. PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, 
and severe depression, respectively. If patients screen as moderate to severe (- PHQ-9 score ≥10), they 
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should be referred to a psychiatrist for treatment initiation, or treatment may be initiated through the 
primary care physician, if preferred.    
Current evidence indicates that only approximately half of cardiovascular physicians are aware 
of CVD in their patients, and roughly a third report that they treat depression in their patients; of those, 
about 70% do not use a validated screening tool  (Feinstein, Blumenfield, Orlowski, Frishman, & 
Ovanessian, 2006), and not all patients who are recognized as depressed are treated (Barth et al.). 
Therefore, CR is an important setting for screening of depression. Indeed the major CR associations 
recommend screening for depression (see Table 2).  
Cardiac Rehabilitation   
CR is an outpatient chronic disease management program. These programs offer comprehensive 
secondary prevention strategies; patients are often seen for a couple of visits per week over several 
months. It is delivered by an interprofessional team, which may include a social worker or psychologist. 
Physical activity is a core component, and has beneficial effects on depressive symptoms (Scholz, Knoll, 
Sniehotta, & Schwarzer, 2006).  Patients receive social support from health care providers and peers. 
Stress management is another core component, and often includes training in relaxation techniques 
which can also ameliorate depression. Finally, guidelines state that patients should be screened for 
depression in these programs (Herridge et al., 2005).  
Since sedentary behavior is considered a risk factor for depression, it stands to reason that it 
also may contribute to depression- and that is exactly what studies have demonstrated (Hughes, Mutrie, 
& Macintyre, 2007; Samartzis et al., 2013). Fortunately, attendance in CR programs has therefore been 
demonstrated to have a mild reduction in exercise symptoms, and since exercise is a vital component of 
the CR model, exercise, independent of other CR components, has been proven to be efficacious at 
treating depression (Milani, Lavie, & Cassidy, 1996). Mechanisms of action revolve largely around up-
regulation of dopamine (which, in depression, is in lowered concentrations in the nucleus accumbens 
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and limbic system, resulting in both dampened emotions and autonomic dysregulation). Increasing 
exercise via upregulation of dopamine ligand-gated receptor channels allows dopamine to remain in the 
intracellular synapse for a longer duration, thereby increasing its effects on the body. Similar 
mechanisms have been examined for serotonin and epinephrine; however, the greatest current 
challenge is that depression does not involve uniform neurotransmitter dampening within the synapse; 
instead, smaller areas are mediated by highly specific types of neurotransmitter receptors, receptor 
densities may fluctuate, and increasing dopamine and serotonin in certain areas of the brain may 
promote depressive symptoms (Dunlop et al., 2007). The complexity of the neuro-architecture is such 
that any of the evidence based treatments that work by specific physiological modulation, such as 
exercise, may address some aspects of depression very well, yet address others poorly (Lambert, 
Johansson, Ågren, & Friberg, 2000). However, due to its efficacy, though mild, exercise should be 
considered a first line recommendation in patients still within the acute grieving stage, which can be 
expected to recede 6-8 months post-event, or for very low levels of depression that can be managed by 
exercise alone.  
Though the benefits of CR are its positive association with lowered depression (Milani & Lavie, 
2007), oftentimes, adherence to CR programs is low (Blanchard et al., 2003). Depressed patients are 
doubly disadvantaged because depression can cause a lack of motivation on top of the main mood 
component; this makes going to participate in physical activity much harder to achieve. For patients who 
do complete CR, reductions in morbidity and mortality remain low, though risk factors tend to decrease 
dramatically as a result of finishing the CR program, much of which can be determined to be a product 
of the CR itself and not any associated antidepressant use, as noted above. 
The guidelines set forth by the American Association of Cardiovascular Prevention and 
Rehabilitation includes recommendations for depression. They are to: initially, identify psychological 
distress as indicated by clinically significant levels of depression using interview and/or standardized 
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measurement tools (PHQ-9, BDI) and offer individual and/or small group education and counseling on 
adjustment to heart disease, stress management, and health-related lifestyle change. When possible, 
include family members, domestic partners, and/or significant others in these sessions, teach and 
support self-help strategies, and finally, arrange for ongoing management if important psychosocial 
issues are present. 
Though screening is definitely important in identifying depressed individuals and referring them 
to appropriate treatment, it has yet to be determined whether mandatory screening is worth the 
expense to the healthcare system, and whether there is a risk of over-diagnosis of depression, leading to 
false-positive results and unnecessary treatments. However, research on screening is scarce: no RCTs 
have been conducted to determine whether screening is taking place, or whether it is effective. A 
current study looked at five journals, 3 of which determined that screening is taking place in the CR 
setting ranging from one-third to over two-thirds of individuals entering CR. Of those being screened, 
the remaining two papers determined that there was no significant difference in depression scores at 
follow-up between patients with higher rates of screening (Cahill, M.C., Bilanovic, A., Kelly, S., Bacon, S., 
& Grace, 2015). 
Depression following major cardiac events is associated with higher mortality, so it has been 
surmised this can be reduced through CR and exercise training. Researchers evaluated the impact of CR 
on depression and its associated mortality in coronary patients by evaluating 522 consecutive coronary 
patients (381 men, 141 women; aged 64+/-10 years) enrolled in CR from January 2000 to July 2005 and 
a control group of 179 patients not completing rehabilitation. Prevalence of depressive symptoms 
decreased 63% following rehabilitation, from 17% to 6% (P <.0001). Depressed patients following 
rehabilitation had an over 4-fold higher mortality than nondepressed patients (22% vs 5%, P=.0004). 
Depressed patients who completed rehabilitation had a 73% lower mortality (8% vs 30%; P=.0005) 
compared with control depressed subjects who did not complete rehabilitation. Reductions in 
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depressive symptoms and its associated mortality were related to improvements in fitness; however, 
similar reductions were noted in those with either modest or marked increases in exercise capacity 
(Milani & Lavie, 2007). Follow-up studies by the same researchers led them to conclude that in patients 
following major coronary events, CR is associated with both reductions in depressive symptoms and the 
excess mortality associated with it. Moreover, only mild improvements in levels of fitness appear to be 
needed to produce these benefits on depressive symptoms and its associated mortality (C J Lavie et al., 
2008; Carl J Lavie et al., 2015). 
A study by Gordon, et al. determined whether patients who take antidepressants derived the 
same benefits from CR in terms of improvements in multiple risk factors (Gordon et al., 2013). A cohort 
of 26,957 CR patients constituted the study population, who were stratified into 3 cohorts (i.e., 
nondepressed, depressed unmedicated, and depressed medicated) at baseline according to a self-
reported history of depression and the current use of antidepressants. Of these patients, 2,147 (41.5%) 
were taking antidepressants. Patients in the nondepressed cohort (49.4% completion) were more likely 
(p <0.001) to complete the entire CR program than patients in the depressed unmedicated (44.5% 
completion) or depressed medicated (43.5% completion) cohorts. Patients in all 3 cohorts who 
completed the exit assessment in their CR program showed significant improvement in multiple risk 
factors. Additionally, the magnitude of improvement in blood pressure, serum lipids and lipoproteins, 
fasting glucose, weight, and body mass index was similar (p >0.05) in patients taking antidepressants 
and those who were not. This study is therefore the first to demonstrate that antidepressants do not 
offset the average magnitude of improvement in multiple atherosclerotic risk factors that occurs with 
completion of a CR program (Gordon et al., 2013). This study underscores the benefits to cardiac 
patients that CR can provide, and that antidepressant therapy may not be accountable for much of the 
improvement that is seen from initiation to CR exit. However, exactly how much benefit CR provides to 
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the patient in terms of relief of depressive symptoms and decreased associated morbidity and mortality 
is still unclear. 
Though depression is being recognized and treated in the CR setting, treatment modalities are 
far from ideal. While antidepressants have shown to be effective at relieving depression, but slightly less 
effective in decreasing the morbidity and mortality associated with cardiovascular disease, they are still 
the treatment of choice for many clinicians, especially in the primary care setting, where specialized 
knowledge of cardiology may be lacking (Khawaja et al., 2009). Antidepressants that patients were 
taking before entering a CR program are often just carried forward unless a specialist is aware of the 
contraindication of TCAs, or to switch from a less efficacious antidepressant (many of the atypicals) to 
an SSRI.  Depression treatment with pharmacological agents, then, can result in conflicting modalities as 
research has not yet been clear as to which antidepressants are both efficacious and well-tolerated by 
the cardiac population. SSRIs certainly seem to be the best option, for now, but the literature is still 
scarce and relatively few studies have even looked at the administration of other classes of 
antidepressants (SNRIs, atypicals) to determine their suitability in this population (Benazon, Nili R., 2005; 
Mamdani, M, Coyne, M, 2005; Judith H Lichtman et al., 2008; Zimmermann-Viehoff et al., 2014). 
Complicating the picture is that the percentage of patients on antidepressants while in CR is not known, 
and is usually estimated based on the percentage of patients with moderate-severe depression while in 
CR; a figure that is approximately 15-30% .However, psychopharmacological agents are not the only 
choice for treatment. Psychotherapy is an option, and of the RCTs that have been conducted, CBT seems 
to be the modality of choice. Whether other types of psychotherapy work as well as CBT in cardiac 
patients can still be considered up for debate; very few studies have even looked at the effectiveness of 
different types of psychotherapy for depression in cardiac populations (Koszycki, Lafontaine, Frasure-
Smith, Swenson, & Lespérance, 2004; Lespérance et al., 2007).  
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Since the literature on the three main types of depression treatment in cardiac settings 
(psychotherapy, pharmacotherapy, and CR) is mixed, and in some cases nonexistent, it is difficult at this 
time to draw firm conclusions on the effects on antidepressant use in CR patients that exhibit depressive 
symptoms. Furthermore, it is difficult to elucidate the effects of the CR program itself- exercise, 
additional social supports, and referrals for psychotherapy- compared to the effects of the 
antidepressants, on a number of domains: mood, risk factors for secondary cardiac events, the 
occurrence of further events, and mortality rates in the years following CR completion.  
 
Objectives 
The objectives of this thesis will be to describe and assess in a large cohort of CR participants: (1) 
changes in depressive symptoms from pre to post-program; (2) class of antidepressants used, in relation 
to evidence and clinical practice recommendations, (3) antidepressant adherence (i.e., proportion of 
days covered and cessation rates), (4) the association between depressive symptoms and 
antidepressant use, and (5) the association between antidepressant use, by class, and the occurrence of 
major adverse coronary events (MACEs) including death.  
Since studies in this area, both RCTs and observational, have shown mixed effects on cardiac 
morbidity and mortality from depression treatments, whether psychopharmacotherapy is an effective 
treatment, and if so, which medication classes should be used. Gaps in the literature exist to determine 
which medications are the most efficacious in terms of both reducing depressive symptoms as well as 
the mortality and morbidity caused by depression, while still remaining safe in cardiac patients. This 
thesis, by way of the objectives outlined above, will examine antidepressant use, both by class and 
individually, and its effects on the number of MACEs experienced by patients over a 10 year post-CR 
follow-up period. Lastly, it will be only study in the literature to our knowledge to report on long term 
antidepressant adherence and outcomes in a cardiac population , as no studies to our knowledge have 
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examined the association between antidepressant use, across all the major, currently-used classes, and 
outcomes in CAD patients; this is particularly notable for including cardiac events , as most studies to 
date look at mortality only. The results of this paper will add more evidence to current literature on the 
effects that antidepressants may have on cardiovascular events, and the increased amount of concrete 
evidence regarding antidepressants and their role in treating depression in CVD patients along with their 
potential effectiveness against CVD-related outcomes may affect treatment recommendations and 
inform current guidelines on depression treatment in cardiac patients.  
METHODS 
DESIGN AND DATA SOURCES 
This was an observational and prospective cohort study, undertaken as secondary analysis. 
Patients with CVD who entered the Mayo Clinic CR program in Rochester, Minnesota between the years 
of 2002 and 2012 will comprise the cohort. Clinical data from CR intake assessments were extracted. 
Patients were administered the PHQ-9 pre and post-program.  
Medication and MACEs were ascertained through record linkage with the Rochester 
Epidemiology Project through to December 2014. This Project is a population-based record linkage 
system which electronically stores the clinical information developed by the Mayo Clinic with that 
obtained by other community providers, the Olmsted Medical Group and the affiliated Olmsted 
Community Hospital that have provided research authorization to the state of Minnesota(Melton, 
1996). The study protocol was approved by both the Mayo Clinic and Olmsted Medical Center 
Institutional Review Board.  
SETTING 
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Residents of Rochester or Olmsted County, Minnesota, and the surrounding area are relatively 
distant from other large metropolitan health care institutions, and hence, the Mayo Clinic CR program 
serves most cardiac patients. The outpatient CR program is 12 weeks in duration, and patients attend 
three times per week for a total of 36 sessions. The program was based on the American Association of 
Cardiovascular and Pulmonary Rehabilitation guidelines (“Guidelines for Cardiac Rehabilitation and 
Secondary Prevention Programs, 5th Edition,” n.d.). 
Each CR session is approximately 60 minutes, of which 40 minutes is exercise time. All patients 
attend group stress management sessions; here, a video is presented which describes how stress affects 
the body, and techniques such as relaxation, exercise and deep breathing. Patients are also provided 
videos to take home addressing relaxation, tai chi/qigong, and mindfulness-based approaches to stress 
management. 
The PHQ-9 (K Kroenke et al., 2001) is administered routinely to all patients at CR intake and 
discharge assessments. Staff discusses abnormal results with patients. Patients with pre-CR scores >5 
are considered for referral to psychiatry; patients expressing suicidal ideation are provided an 
emergency consult. Psychiatrists may then prescribe pharmacotherapy or other treatments.  
PARTICIPANTS 
Inclusion criteria were patients 18 years of age or older, with a documented diagnosis of CVD, 
who attended the CR program. CAD was defined as: (1) a previous myocardial infarction (ST or non-ST-
segment elevation), (2) stable or unstable angina, and/or (3) previous revascularization by either CABG 
or PCI. In order to facilitate outcome assessment, an additional inclusion criterion was that patients 
were to be residents of Olmsted County, Minnesota. Patients who did not complete the post-CR PHQ-9 
were excluded. 
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MEASURES 
 Most participant characteristics were obtained from the record linkage system. Clinical 
characteristics to be extracted include CR referral indication, comorbidities and cardiac risk factors. 
Sociodemographic characteristics will include ethnicity, age, and sex. Smoking history was obtained from 
the electronic medical record, based on self-report to a healthcare provider. The date of CR intake was 
recorded.  
Medications were also available through the record linkage system. Psychiatric medications 
were extracted from 2001 to the end of 2014. Variables were computed to specify medication class 
(e.g., anti-depressant categories were five-fold: Selective Serotonin Re-uptake Inhibitors [SSRIs], 
Serotonin-Norepinephrine Re-uptake Inhibitors [SNRIs], TCAs, atypicals, and others [MAOIs]; other 
psychiatric medications [e.g., benzodiazepines, antipsychotics]). Proportion of days covered will also be 
computed (i.e., proportion of days in the measurement period the participant had filled a prescription 
for the medication, which is an indicator of medication adherence)(Ho, Bryson, & Rumsfeld, 2009), and 
whether the patients initiated the medication before, during or after CR.  
Independent Variable 
The PHQ-9 (Appendix A) is a multi-purpose instrument for screening, diagnosing, monitoring and 
measuring the severity of depression (K Kroenke et al., 2001), recommended for administration in 
cardiac samples (Judith H Lichtman et al., 2008). The tool assesses the criteria on which the diagnosis of 
depressive disorder is based (American Psychiatric Association, 1994). Response options for each item 
range from 0 “not at all” to 3 “nearly every day”, with greater scores reflective of greater 
symptomatology. It yields both a provisional depression diagnosis and a severity score (K Kroenke et al., 
2001).  
Major depression is considered if 5 or more of the 9 depressive symptom criteria have been 
present at least “more than half the days” (response option 2) in the past 2 weeks, and one of the 
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symptoms is depressed mood or anhedonia. Question 9 screens for the presence and duration of 
suicidal ideation and counts if present at all, regardless of frequency. A follow-up, non-scored question 
screens and assigns weight to the degree to which depressive symptoms have affected the patient’s 
functioning.  
PHQ-9 total scores range from 0 to 27. Cut-points of 5, 10, 15, and 20 represent the thresholds 
for mild, moderate, moderately severe, and severe depression, respectively (Gilbody et al., 2008). A 
single cut-point is currently recommended at a score of 10 or greater (i.e., “elevated” symptoms), as this 
has a sensitivity for depression of 88%, a specificity of 88%, and a positive likelihood ratio of 7.1 (K 
Kroenke et al., 2001). The minimal clinically important difference (MCID) to be used for the analysis 
were 5 points or greater, as described by Lowe et al.(Lowe B, Unutzer J, Callahan CM, Perkins AJ, 2004). 
Dependent Variables 
Subsequent clinical events were ascertained using the record linkage system from the Rochester 
Epidemiology Project. MACEs included any of the following events: acute coronary syndrome 
(myocardial infarction [ICD-9, 410.x] or unstable angina [ICD-9, 411.x), coronary revascularization 
(Coronary Artery Bypass Graft [CABG; CPT/ICD-9 337700-337735/V45.81] surgery or Percutaneous 
Coronary Intervention [PCI; CPT/ICD-92980-92982/V45.82]), ventricular arrhythmias that required in-
hospital management (ICD-9 427.X), or death from any cause. Mortality information was obtained 
directly from the REP, which records vital status from state vital statistics offices and the National Death 
Index. (St Sauver et al., 2012)  
All outcome information were followed passively, through electronic ascertainment using 
diagnosis codes. A physician-investigator / co-author (JMI), who were blinded to baseline characteristics, 
will review a fraction of the records in the record-linkage system to confirm the outcome and validate 
the research strategy. Additionally, a random 10% of the outcomes were reviewed in duplicate by a 
clinician expert / senior author (FLJ), with excellent inter-observer agreement. 
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STATISTICAL ANALYSES 
First, the differences in sociodemographic and clinical characteristics of participants who were 
retained post-CR (i.e., completed PHQ-9 post-program) versus lost to follow-up were compared using t-
tests or chi-square, as appropriate. To test the first objective, a descriptive examination of depressive 
symptoms pre and post-CR were performed in the retained sample, and a paired t-test were run. To test 
the second objective, anti-depressants use were described, and these were coded by class (i.e., SSRIs, 
SNRIs, TCAs, and atypicals). Further calculations include specifying whether antidepressants were used 
during CR specifically. To test the third objective, adherence to these antidepressants were 
operationalized by proportion of days covered. To test the fourth objective, associations between 
depressive symptoms and antidepressant use were calculated using t-tests, both independent samples 
and paired.  
To test the last objective, Kaplan-Meier curves were generated, though hazard time was used 
instead of survival time to represent risk of MACE due to the possibility of multiple MACEs occurring. 
Finally, adjustment for covariates across the time-dependent model was computed via a Cox regression 
analysis, which tests the association between depressive symptom change and antidepressant use 
(independent variables) on MACE hazard risk, while adjusting for clinical characteristics which were 
significantly different between retained patients versus those lost to follow-up. 
RESULTS 
Respondent Characteristics 
Overall, 1964 patients initiated CR during the period of study, of which 1266 (74.7%) completed 
the follow-up PHQ-9 and comprised the sample. Their characteristics are shown in Table 1. As shown, 
retained participants did not differ with regard to sociodemographic characteristics from those lost to 
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follow-up. However, retained participants were significantly more likely to be referred to CR for 
peripheral vascular disease, stroke, and heart failure, more often smoked, and had chronic kidney 
disease than those lost to follow-up. Moreover, retained participants had significantly lower depressive 
symptoms pre-CR and were more likely to be taking any anti-depressant than those lost to follow-up. 
DEPRESSIVE SYMPTOMS- OBJECTIVE ONE 
Mean depressive symptom scores, severity categorizations and provisional diagnoses based on 
the PHQ-9 scores pre and post-CR are shown in Table 2, as per objective one. As shown, most 
participants scored in the minimal range pre and post-CR. Women had significantly higher depressive 
symptom scores pre-CR (mean ± standard deviation=5.41±5.29 females vs 4.78±5.14 males, p=0.04), 
though not post (3.74±4.47 vs 3.49±4.40, p=0.35). All depressive symptom indicators decreased 
significantly from pre to post-program.  
Overall, 220/1266 (17.4%) participants scored in the “elevated” range pre-CR (i.e. >10), and 
125/1266 (9.9%) at post-test. Participants were categorized based on scoring above or below 10 on the 
PHQ-9 both pre and post-CR. Results showed that 984/1266 (77.7%) remained subclinical throughout 
CR, 115/1266 (9.1%) went from elevated to subclinical, 46/1266 (3.6%) went from subclinical to 
elevated, and 49 (3.9%) remained elevated.   
Of participants with elevated depressive symptoms pre-CR, their mean PHQ-9 score post-CR was 
7.30±6.36. Overall, 983 (77.6%) participants’ PHQ-9 scores did not change either higher or lower than 
the MCID of 5 from pre to post-CR, but for 204 (16.1%) participants their scores decreased at least 5 or 
more, and for 79 (6.2%) their scores increased at least 5 or more.  
ANTIDEPRESSANT USE- OBJECTIVE TWO 
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Overall, 446 (35.2%) participants were taking any psycho-pharmacological medication, with 
278/446 (62.3%) taking more than one (mean 2.70±0.97 medications/patient; median=2). Significantly 
more women than men were on antidepressants (n=162, 39.3% women vs. n=271, 31.6% men, p<0.01).  
Class of antidepressant used is shown in Table 3, as per objective 2. As shown, most participants 
were on SSRIs (most commonly citalopram 132 [10.4%], sertraline 101 [8.0%], and paroxetine 36 
[2.8%]), followed by atypical antidepressants (most commonly trazodone 106 [8.4%], bupropion 72 
[5.7%], and mirtazapine 31 [2.4%]), TCAs (most commonly amitriptyline 50 [3.9%], nortriptyline 39 
[3.1%]; and trimipramine 7 [0.6%]), and SNRIs (only venlafaxine 54 [3.2%], and duloxetine 31 [1.8%]). No 
participants were on any other class of antidepressant (e.g., monoamine oxidase inhibitors). Other 
psychoactive medications participants were taking were: sedatives (n=63, 5.0%; e.g., zolpidem, n=51, 
4.0%), benzodiazepines (n=67, 5.3%; e.g., lorazepam n=63, 3.7%), antipsychotics (n=25, 2.0%; e.g., 
quetiapine, n=22, 1.3%), stimulants (n=5, 0.4%; e.g., modafinil n=5, 0.4%), and mood stabilizers (lithium 
n=3, 0.3%).  
MEDICATION ADHERENCE- OBJECTIVE THREE 
Participants were on their antidepressant for an average of 4.39±3.19 years during the period of 
study (objective 3). Of those taking the major classes of antidepressants, 33/62 (53.2%) stopped taking 
SNRIs, 153/299 (51.2%) stopped taking SSRIs, 80/179 (44.7%) stopped taking atypicals, and 38/102 
(37.3%) stopped taking TCAs during the period of study. With regard to proportion of days covered, 
participants were most adherent to atypicals (72.4%), followed by TCAs (71.8%), SSRIs (71.7%), and 
finally SNRIs (68.5%). Degree of adherence to any class of anti-depressants was not significantly 
associated with post-CR depressive symptoms (all p>0.05).  
DEPRESSION SYMPTOMS AND ANTIDEPRESSANT USE- OBJECTIVE FOUR 
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With regard to objective four, among the 220/1266 (17.4%) participants with elevated PHQ-9 
scores pre-CR, 202/220 (91.8%) were on any antidepressant medication during CR, and this was 
significantly greater than among those without elevated scores (188/1046 [18.0%]; p<0.001). Moreover, 
among participants on any antidepressant during CR, their mean pre-CR PHQ-9 scores were 7.33±5.94, 
and post-CR scores were 4.69±4.87 (paired t=6.17, p<0.001; Figure 1). These scores were significantly 
higher than participants not on antidepressants both pre (4.98±5.20, p<0.001) and post-CR (3.57±4.43, 
paired t= 9.75, p<0.001).  
MACES, AND THEIR ASSOCIATIONS WITH DEPRESSIVE SYMPTOMS AND ANTIDEPRESSANT USE  
Overall, there were 264 patients who had any MACE. MACEs are shown in Table 3; as shown in 
the total column, one-fifth of participants had a MACE, and this was most frequently PCI, followed by 
angina and myocardial infarction. Moreover, 151/329 (45.9%) had more than one MACE, and these 
participants had a mean of 2.36±1.24 MACEs (median=2). The mean time to the first MACE from CR 
initiation was 392.21±421.74 days. For participants who died, the mean time to mortality was 
457.29±467.71 days. 
Greater pre-CR depressive symptoms were significantly associated with the occurrence of 
MACEs, specifically percutaneous coronary intervention (t=2.86, p=0.04), myocardial infarction (t=2.42, 
p=0.02), heart failure (t=2.59, p=0.01), and death (t=2.88, p<0.01). Moreover, the number of MACEs was 
significantly and positively associated with greater pre-CR depressive symptoms (r=0.10,  p<0.01).  
Proportion of days covered on any antidepressant class was not significantly associated with 
occurrence of any MACEs (all p>0.05), except for in those taking SSRIs (74.62±11.91% adherence in 
participants with any MACE vs 69.57±14.32% adherence in participants having no MACEs, p=0.02).  
Proportion of days covered on any class was not significantly associated with death (all p>0.05). 
With regard to the final objective, occurrence of any MACE including death was significantly 
higher in participants taking any antidepressant at any time point (n=168/433, 38.8%) than participants 
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not taking an antidepressant (n=223/833, 26.8%; p<0.001). As shown in Table 3, use of antidepressants 
of any class was significantly associated with more MACEs. PCI in particular was more frequent among 
participants taking an antidepressant of any class when compared to participants not taking 
antidepressants from that class. Death was significantly more common among participants taking TCAs 
than those not taking TCAs. The number of ventricular arrhythmias was low, and hence results should be 
interpreted with caution. Myocardial infarction and heart failure were more common in participants 
taking SSRIs, and the highest proportion of MACEs overall occurred in participants taking this class of 
antidepressants. Overall, participants taking SNRIs had the least MACEs. There were no antidepressants 
used associated with significantly fewer MACEs.  
Table 4 displays the Cox regression model of factors associated with time to first MACE. The 
overall model, which adjusted for depressive symptoms, was significant (χ2=25.49, p<0.01).  As shown, 
over and above history of peripheral vascular disease and heart failure, use of TCAs was significantly 
related to greater MACE hazard. No other antidepressants were associated with MACEs in the adjusted 
model. A Kaplan-Meier survival curve displaying time to MACE by use of TCAs is shown in Figure 2. 
Discussion 
In a population-based cohort, this study has shown that participation in CR is associated with 
significant reductions in depressive symptoms, and these are clinically-significant reductions among 
those with elevated symptoms. Approximately one-third of cardiac patients were on an antidepressant, 
with almost half of these patients starting an antidepressant during CR. Most participants were taking 
the recommended class of antidepressants; but some patients were taking antidepressants which have 
not been well-studied in the CVD population (i.e., SNRIs), and unfortunately even which are often 
contraindicated in this population (i.e., TCAs). Patients were on their antidepressants for an average of 
four years, and took their medication about three-quarters of the time. One-third to one-half of 
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participants stopped taking an antidepressant during the period of study, depending on the class. While 
antidepressant use was associated with reductions in depressive symptoms, unfortunately use of TCAs 
specifically was associated with poorer cardiovascular outcomes, including death. MACEs occurred 93% 
sooner among patients on a TCA. 
Almost one-fifth of CR participants had elevated depressive symptoms, which is consistent with 
what is reported in the literature. Use of antidepressants in this cohort (approximately one-third) was 
much higher however, than what has previously been reported in the literature (10-15%)(Thombs et al., 
2005)(Czarny et al., 2011; Grace et al., 2008), although the review by Czarny et al. noted higher rates in 
the United States (from where this cohort stems), and increasing rates over time. Given depression has 
been historically under-recognized and treated, the results herein suggest symptoms are being detected 
and managed in accordance with the AHA recommendations (Lichtman et al., 2008); although there may 
be a trend toward over-prescribing (i.e., rates of use 10% higher than the average burden of depression 
of 20% in this population, and two-thirds taking more than one antidepressant [although combination 
augmentation strategies can increase remission]) (Moret, 2005).  Adherence to therapy (Nwokeji et al., 
2012), and discontinuation rates were consistent with what has been described in the literature (Geddes 
et al., 2003). This is one of the only studies in the literature to our knowledge to report on 
antidepressant adherence indicators in a cardiac population. 
In accordance with clinical recommendations for CVD patients with depression, most 
participants were on first-line recommended therapy, namely SSRIs, or second-line therapies, namely 
atypicals (Bradley et al., 2015). While SNRIs are considered as potential second-line therapy for CVD 
patients, they are unstudied in this population (Bradley et al., 2015). While few patients were on SNRIs 
in the cohort and therefore lack of association could be due to low power, the results did suggest few 
MACEs in patients taking SNRIs. In fact, their safety profile was superior to the recommended first-line 
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therapy of SSRIs. Indeed, there has been some suggestion that SSRIs may not be as safe as previously 
described (Fosbol et al., 2009; Pacher & Kecskemeti, 2004).  
While patients were given antidepressants and their treatment appeared to be managed in 
accordance with recommendations, the depression-mitigating effects of the patients’ CR program, 
especially the exercise component, cannot be ignored. Since patients were assessed for depression at 
CR intake and exit, there was a roughly 3-month period during which patients were on a regimen of 
exercise and possibly antidepressants. A mean decrease of PHQ-9 scores from 4.98 to 3.57 during CR 
was observed overall; the decrease is relatively modest and may be attributable to increased exercise 
accompanying the CR program. However, looking at patients with “severe” depression, the proportion 
was more than halved from 2.5% of the depressed population to only 1.2%. Severe and refractory 
depression does not respond well to exercise-only therapies (Cooney et al., 2013; Mota-Pereira et al., 
2011), so it is unlikely that the entirety of the reduction in depressive symptoms could be explained by 
exercise in CR. However, for the mild-to-moderately depressed cardiac patients, exercise may well be a 
useful intervention in lowering their depressive symptoms, and may have played a small role in 
depressive symptom improvement over the course of their CR program. 
Use of TCAs in the cohort was associated with MACEs, as has been established in the literature 
(Bradley et al., 2015). Appropriately, rates of use were low, consistent with previous research 
(Zimmermann-Viehoff et al., 2014), and may have been in patients who were not early post-myocardial 
infarction or at risk of long QT, or who suffered severe depression and were non-responsive to SSRIs 
(i.e,. appropriateness cannot be ascertained from the data at hand). For patients who were on TCAs 
prior to CVD diagnosis, clinicians can taper the TCA, and either wait until it is finished, or slowly 
introduce an SSRI during the taper (British Columbia Public Health, 2013).  
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The mechanisms by which antidepressant classes may cause MACEs should be considered. TCAs 
have been well-established to cause arrhythmogenic events; most commonly, sinus tachycardia, 
brachial tachycardia, atrial fibrillation, and intraventricular conduction deficits. For this reason, the 
arrhythmia caused by TCAs is often severe in consequence (Fasoli & Glauser, 1981).  Cardiac 
abnormalities are well known and understood with TCAs; essentially, TCAs are known to cause blockage 
of sodium through ion-gated channels responsible for the entire action potential and refractory period 
of a heartbeat. The increased extracellular sodium then causes hyperpolarization of the extracellular 
matrix, making an action potential less likely to occur with a given amount of positive ions inside the 
cell. The elongation of this timeframe, where sodium ions are slowly entering the cell but are somewhat 
blocked, is known as the QT interval and is the refractory period between action potential cycles (Pacher 
& Kecskemeti, 2004). Mechanism-wise, drug interactions may exacerbate certain conditions; for 
example, fluoxetine’s long half-life is increased in heart failure patients, and bupropion causes increased 
blood pressure. Both of these medications end up elongating the QT interval and patients should be 
monitored closely for signs of MI. 
None of the other antidepressant classes examined in this thesis has so far been associated with 
cardiotoxicity; however, a large number of non-fatal cardiac events were associated with SSRI usage 
(Table 3). No literature seems to discuss cardiac events in non-overdose cases (except Selective 
Serotonin Toxicity in overdose; the release of Serotonin through the CNS where it is mainly stored and 
potentially affecting QT intervals). In usual dose, risk of QT appears to be understudied in the literature. 
One study found that by electrocardiography, QT prolongation appears to be linked to SSRI use, and is 
similar to that seen in patients on TCAs; the main difference being the length of the QT prolongation as 
it is longer in patients on TCAs (Açikalin et al., 2010). In addition, citalopram, due to its increased risk of 
serotonin toxicity, is associated with dose-dependent QT interval prolongation and is contra-indicated in 
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patients with known QT interval prolongation or congenital long QT syndrome, according to the 
Canadian Network of Mood and Anxiety Disorders (Ramasubbu et al., 2012). 
Results herein regarding poorer outcomes among CVD patients taking antidepressants are 
consistent with previous literature (which has been primarily in HF populations taking SSRIs) (Diez-
Quevedo et al., 2013; Veien et al., 2011), although results are not consistent with all literature (Diez-
Quevedo et al., 2013; Fosbol et al., 2009). For instance, the results herein are contrary to the findings by 
Connor et al., that the association between SSRI use and mortality was mitigated by depressive 
symptoms (Grace et al., 2008; MacGillivray et al., 2003; O’Connor et al., 2008); while our model adjusted 
for depressive symptoms, they were not significant. This incongruence could be explained by the fact 
that all patients in the current study participated in CR, which is associated with lower depression 
(Rutledge et al., 2013). In the Heart and Soul study, CVD patients more broadly were included (not just 
HF) as in the current study, and 2 classes of antidepressants were considered (not just SSRIs, but also 
TCAs). Similar to the findings herein, TCAs but not SSRIs were associated with increased mortality 
(Zimmermann-Viehoff et al., 2014). We could find no studies comparing MACEs in cardiac patients 
across each of the 4 of the major antidepressant classes, and hence again this study represents an 
important contribution to the literature. However, Rutledge et al. undertook a review of the effects of 
mental health treatments (a composite of psychotherapy and antidepressants) versus CR on 
MACEs(Rutledge et al., 2013). In his work, it was shown that treatment of depression, by any of these 
strategies including CR, was associated with significantly fewer MACEs. Again, in the current study we 
did not observe lower MACEs with use of any antidepressant class. The inconsistency between these 
findings is likely due to the capacity herein to focus on individual antidepressant classes, and the lack of 
consideration of psychotherapy. 
Mechanisms 
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Lastly, it is worth mentioning that in all of the literature that currently exists regarding 
antidepressants, cardiac patients, CR, and MACEs, the commonalities appear to be that depression is an 
independent predictor of mortality and morbidity, that CR decreases depression symptoms by its 
multifaceted approach, and that a new strategy to look at this problem may be needed in order to 
elucidate the effects of specific factors (like antidepressants) on MACE events in cardiac patients, while 
considering the effects of confounders. So far, there has been no model that has been able to do that 
well. This study may be the first in the area to take a microscopic approach to a macroscopic system; 
looking at a large, complex issue made up of many sub-issues, and focusing only on a few small, specific 
factors that would be relevant to the gap in the literature that requires further study.  A diagram is 
presented in Appendix D which displays the potential pathways from depression to CVD events in 
cardiac patients. Conceptually, these factors are so integrally related that the best course of action may 
be to untangle them from a very basic level; here we have decided to look at the pathway mediated by 
antidepressants and how pharmacotherapy might change CVD outcomes in a CR population.  
Limitations 
Caution is warranted in interpreting the results. First, with regard to design, this study lacked a 
control group who was not exposed to CR, and therefore history and maturation effects will not be able 
to be ruled out. Second, the design was observational, and hence causal conclusions were not able to be 
drawn. Third, as a secondary analysis, it was not be powered specifically for the current analysis.  
Fourth, with regard to generalizability, it must be conceded it was limited as the data stems 
from a single center. However, the CR center is the only one available in the region, and therefore 
findings should be fairly representative of patients who attend CR in general. It is unknown how 
generalizable the results are to cardiac patients more broadly; however there are systematic referral 
processes in place at the Mayo Clinic for those with insurance coverage.  
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Fifth, there was some retention bias in the sample particularly that retained patients had less 
depressive symptoms and use of anti-depressants than those lost to follow-up. Sixth, with regard to 
measurement, there was no structured clinical interview. Therefore, no definitive diagnosis of 
depression can be inferred from the data. Seventh, multiple comparisons were undertaken to assess the 
associations between antidepressant classes and specific MACEs, and therefore some of the associations 
observed may be spurious. Finally, while all CR participants were exposed to stress management, use of 
psychotherapy, which is another evidence-based treatment for depression, was not known and 
therefore cannot be considered in the analyses. It is not captured at the Mayo Clinic CR program. 
Conclusions 
In summary, depression is successfully detected and managed in the CR setting, with patients 
generally being prescribed antidepressants in accordance with clinical practice guideline 
recommendations, and use of combination/augmentation strategies to optimize symptom reduction. 
Use of antidepressants was associated with lower depression, but often more adverse events. While not 
associated with MACEs in the adjusted model, the safety profile of SNRIs warrants further consideration; 
emerging evidence may warrant changes to prescribing recommendations in this population. Further 
research is also needed on approaches and impact of tapering CVD patients off TCAs.  
  
 52  
References 
AACVPR. (2013). American Association of Cardiovascular and Pulmonary Rehabilitation. Guidelines for 
Cardiovascular and Secondary Prevention Programs. 5th edition. Champaign, IL: Human Kinetics; 
(5th ed.). Human Kinetics; US. 
Açikalin, A., Satar, S., Avc, A., Topal, M., Kuvandk, G., & Sebe, A. (2010). QTc Intervals in Drug Poisoning 
Patients with Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors. American 
Journal of Therapeutics, 17(1), 30–33. http://doi.org/10.1097/MJT.0b013e318197eec6 
American Psychiatric Association. (1994). American Psychiatric Association Task Force on DSM-IV. 
Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. 
Anderson, L. J., & Taylor, R. S. (2014). Cardiac rehabilitation for people with heart disease : An overview 
of Cochrane systematic reviews ☆. International Journal of Cardiology, 177(2), 348–361. 
http://doi.org/10.1016/j.ijcard.2014.10.011 
APA. (2013). Major Depressive Disorder and the Bereavement Exclusion. 
Barth, J., Härter, M., Paul, J., & Bengel, J. [Treatment of patients with coronary heart disease and 
depressive disorders in rehabilitation]. Psychotherapie, Psychosomatik, Medizinische Psychologie, 
55(9–10), 416–24. http://doi.org/10.1055/s-2005-866902 
Baumeister, H., Hutter, N., & Bengel, J. (2011). Psychological and pharmacological interventions for 
depression in patients with coronary artery disease. In H. Baumeister (Ed.), Cochrane Database of 
Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd. 
http://doi.org/10.1002/14651858.CD008012.pub3 
Benazon, Nili R. PhD; Mamdani, Muhammad M. PharmD; Coyne, J. C. P. (2005). Trends in the Prescribing 
of Antidepressants Following Acute Myocardial Infarction, 1993–2002. Psychosomatic Medicine. 
Berkman, L. F., Blumenthal, J., Burg, M., Carney, R. M., Catellier, D., Cowan, M. J., … Schneiderman, N. 
(2003). Effects of Treating Depression and Low Perceived Social Support on Clinical Events After 
Myocardial Infarction. JAMA, 289(23), 3106. http://doi.org/10.1001/jama.289.23.3106 
Bjarnason-Wehrens, B., McGee, H., Zwisler, A.-D., Piepoli, M. F., Benzer, W., Schmid, J.-P., … Mendes, M. 
(2010). Cardiac rehabilitation in Europe: results from the European Cardiac Rehabilitation 
 53  
Inventory Survey. European Journal of Cardiovascular Prevention and Rehabilitation : Official 
Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and 
Cardiac Rehabilitation and Exercise Physiology, 17(4), 410–8. 
http://doi.org/10.1097/HJR.0b013e328334f42d 
Blanchard, C. M., Courneya, K. S., Rodgers, W. M., Fraser, S. N., Murray, T. C., Daub, B., & Black, B. 
(2003). Is the theory of planned behavior a useful framework for understanding exercise 
adherence during phase II cardiac rehabilitation? Journal of Cardiopulmonary Rehabilitation, 23(1), 
29–39. 
Bradley, S. M., Rumsfeld, J. S., Hirschfeld, R. M., Keller, M. B., Panico, S., Arons, B. S., … Vieweg, W. V. R. 
(2015). Depression and cardiovascular disease. Trends in Cardiovascular Medicine, 25(7), 614–22. 
http://doi.org/10.1016/j.tcm.2015.02.002 
Bradley SM, R. J. (2015). Depression and cardiovascular disease. Trends Cardiovasc Med, 25(7), 614–622. 
http://doi.org/10.1016/j.tcm.2015.02.002 
British Columbia Public Health. (2013). Major Depressive Disorder in Adults: Diagnosis &amp; 
Management. 
Buckley, J. P., Furze, G., Doherty, P., Speck, L., Connolly, S., Hinton, S., & Jones, J. L. (2013). BACPR 
scientific statement: British standards and core components for cardiovascular disease prevention 
and rehabilitation. Heart (British Cardiac Society), 99(15), 1069–71. 
http://doi.org/10.1136/heartjnl-2012-303460 
CACPR. (2016). CCRR Patient Information Cardiac Rehab Program. 
Cahill, M.C., Bilanovic, A., Kelly, S., Bacon, S., & Grace, S. L. (2015). Screening for depression in cardiac 
rehabilitation: A review. Journal of Cardiopulmonary Rehabilitation and Prevention, 35(4), 225–
230. 
Ceccarini, M., Manzoni, G. M., Castelnuovo, G., Ceccarini, M., Manzoni, G. M., & Castelnuovo, G. (2014). 
Assessing Depression in Cardiac Patients: What Measures Should Be Considered? Depression 
Research and Treatment, 2014, 1–17. http://doi.org/10.1155/2014/148256 
Cohen, B. E., Edmondson, D., & Kronish, I. M. (2015). State of the Art Review: Depression, Stress, 
Anxiety, and Cardiovascular Disease. American Journal of Hypertension, 28(11), 1295–302. 
 54  
http://doi.org/10.1093/ajh/hpv047 
Cooney, G. M., Dwan, K., Greig, C. A., Lawlor, D. A., Rimer, J., Waugh, F. R., … Mead, G. E. (2013). 
Exercise for depression. The Cochrane Database of Systematic Reviews, (9), CD004366. 
http://doi.org/10.1002/14651858.CD004366.pub6 
Czarny, M. J., Arthurs, E., Coffie, D.-F., Smith, C., Steele, R. J., Ziegelstein, R. C., & Thombs, B. D. (2011). 
Prevalence of antidepressant prescription or use in patients with acute coronary syndrome: a 
systematic review. PloS One, 6(11), e27671. http://doi.org/10.1371/journal.pone.0027671 
Davidson, K. W. (2015). Comparison of Depression Identification After Acute Coronary Syndrome: 
Quality of Life and Cost Outcomes. Retrieved from 
https://clinicaltrials.gov/ct2/show/record/NCT01993017?term=davidson+screening&rank=3 
Davidson, K. W., Bigger, J. T., Burg, M. M., Carney, R. M., Chaplin, W. F., Czajkowski, S., … M, G. (2013). 
Centralized, Stepped, Patient Preference–Based Treatment for Patients With Post–Acute Coronary 
Syndrome Depression. JAMA Internal Medicine, 173(11), 997. 
http://doi.org/10.1001/jamainternmed.2013.915 
Davidson, K. W., Kupfer, D. J., Bigger, J. T., Califf, R. M., Carney, R. M., Coyne, J. C., … Suls, J. M. (2006). 
Assessment and Treatment of Depression in Patients With Cardiovascular Disease: National Heart, 
Lung, and Blood Institute Working Group Report. Psychosomatic Medicine, 68(5), 645–650. 
http://doi.org/10.1097/01.psy.0000233233.48738.22 
Davidson, K. W., Rieckmann, N., Clemow, L., Schwartz, J. E., Shimbo, D., Medina, V., … CJ, M. (2010). 
Enhanced Depression Care for Patients With Acute Coronary Syndrome and Persistent Depressive 
Symptoms. Archives of Internal Medicine, 170(7), 2763–2774. 
http://doi.org/10.1001/archinternmed.2010.29 
Davidson, P. M., Phillips, J. L., Dennison-Himmelfarb, C., Thompson, S. C., Luckett, T., & Currow, D. C. 
(2016). Providing palliative care for cardiovascular disease from a perspective of sociocultural 
diversity. Current Opinion in Supportive and Palliative Care, 10(1), 11–17. 
http://doi.org/10.1097/SPC.0000000000000188 
Diez-Quevedo, C., Lupón, J., González, B., Urrutia, A., Cano, L., Cabanes, R., … Bayes-Genis, A. (2013). 
Depression, antidepressants, and long-term mortality in heart failure. International Journal of 
 55  
Cardiology, 167(4), 1217–1225. http://doi.org/10.1016/j.ijcard.2012.03.143 
Dunlop, B. W., Nemeroff, C. B., A, C., JJ, S., W, S., P, W., … S, P. (2007). The Role of Dopamine in the 
Pathophysiology of Depression. Archives of General Psychiatry, 64(3), 327. 
http://doi.org/10.1001/archpsyc.64.3.327 
ENRICHD Investigators. (n.d.). Enhancing Recovery in Coronary Heart Disease (ENRICHD) study 
intervention: rationale and design. Psychosomatic Medicine, 63(5), 747–55. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/11573023 
Fasoli, R. A., & Glauser, F. L. (1981). Cardiac Arrhythmias and ECG Abnormalities in Tricyclic 
Antidepressant Overdose. Clinical Toxicology, 18(2), 155–163. 
http://doi.org/10.3109/15563658108990022 
Feinstein, R. E., Blumenfield, M., Orlowski, B., Frishman, W. H., & Ovanessian, S. (2006). A national 
survey of cardiovascular physicians’ beliefs and clinical care practices when diagnosing and treating 
depression in patients with cardiovascular disease. Cardiology in Review, 14(4), 164–169. 
http://doi.org/10.1097/01.crd.0000200977.41695.43 
Fosbol, E. L., Gislason, G. H., Poulsen, H. E., Hansen, M. L., Folke, F., Schramm, T. K., … Torp-Pedersen, C. 
(2009). Prognosis in Heart Failure and the Value of  -Blockers Are Altered by the Use of 
Antidepressants and Depend on the Type of Antidepressants Used. Circulation: Heart Failure, 2(6), 
582–590. http://doi.org/10.1161/CIRCHEARTFAILURE.109.851246 
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003). 
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic 
review. The Lancet, 361(9358), 653–661. http://doi.org/10.1016/S0140-6736(03)12599-8 
Geggel L, W. S. (2015). The 10 Happiest Countries Are All in Latin America. 
Gilbody, S., Sheldon, T., & House, A. (2008). Screening and case-finding instruments for depression: a 
meta-analysis. CMAJ : Canadian Medical Association Journal = Journal de l’Association Medicale 
Canadienne, 178(8), 997–1003. http://doi.org/10.1503/cmaj.070281 
Glassman, A. H., O’Connor, C. M., Califf, R. M., Swedberg, K., Schwartz, P., J. Thomas Bigger, J., … RM, C. 
(2002). Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina. 
JAMA, 288(6), 701. http://doi.org/10.1001/jama.288.6.701 
 56  
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., … Turner, M. B. (2013). 
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. 
Circulation, 127(1), e6–e245. http://doi.org/10.1161/CIR.0b013e31828124ad 
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., … Wilson, P. W. F. 
(2014). 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American 
College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the 
American College of Cardiology, 63(25 Pt B), 2935–59. http://doi.org/10.1016/j.jacc.2013.11.005 
Gordon, N. F., Habib, A., Salmon, R. D., Bishop, K. L., Drimmer, A., Reid, K. S., … Sperling, L. S. (2013). 
Effect of exercise-based cardiac rehabilitation on multiple atherosclerotic risk factors in patients 
taking antidepressant medication. American Journal of Cardiology, 111(3), 346–351. 
http://doi.org/10.1016/j.amjcard.2012.10.011 
Grace, S. L., Leung, Y. W., & Stewart, D. E. (2008). A prospective examination of antidepressant use and 
its correlates in patients with acute coronary syndrome. Psychosomatics, 49(3), 199–207. 
http://doi.org/10.1176/appi.psy.49.3.199 
Grace, S. L., Turk-Adawi, K. I., Contractor, A., Atrey, A., Campbell, N., Derman, W., … Lopez-Jimenez, F. 
(2016). Cardiac rehabilitation delivery model for low-resource settings. BMJ Heart. 
http://doi.org/10.1136/ 
Grace, S. L., Warburton, D. R., Stone, J. a, Sanderson, B. K., Oldridge, N., Jones, J., … Buckley, J. P. (2013). 
International Charter on Cardiovascular Prevention and Rehabilitation: a call for action. Journal of 
Cardiopulmonary Rehabilitation and Prevention, 33(2), 128–31. 
http://doi.org/10.1097/HCR.0b013e318284ec82 
Guidelines for Cardiac Rehabilitation and Secondary Prevention Programs, 5th Edition. (n.d.). Retrieved 
October 13, 2015, from http://www.humankinetics.com/guidelines-for-cardiac-rehabilitation-and-
secondary-prevention-programs-5th-edition 
Gulliksson, M., Burell, G., Lundin, L., Toss, H., Svärdsudd, K., Rosengren, A., … Schneiderman, N. (2007). 
Psychosocial factors during the first year after a coronary heart disease event in cases and 
referents. Secondary Prevention in Uppsala Primary Health Care Project (SUPRIM). BMC 
Cardiovascular Disorders, 7(1), 36. http://doi.org/10.1186/1471-2261-7-36 
 57  
Haddadzadeh, M. H., Maiya, A. G., Shad, B., Mirbolouk, F., & Padma Kumar, R. (2011). Effectiveness of 
cardiac rehabilitation on left ventricular ejection fraction in post-coronary event patients: A 
successful model for developing countries. Canadian Journal of Cardiology, 27(5), S242. 
http://doi.org/http://dx.doi.org/10.1016/j.cjca.2011.07.416 
Halaris, A. (2009). Comorbidity between depression and cardiovascular disease. International 
Angiology : A Journal of the International Union of Angiology, 28(2), 92–9. 
Hare, D. L., Toukhsati, S. R., Johansson, P., & Jaarsma, T. (2014). Depression and cardiovascular disease: 
a clinical review. European Heart Journal, 35(21), 1365–72. 
http://doi.org/10.1093/eurheartj/eht462 
Hazinski, M. F., Nolan, J. P., Aickin, R., Bhanji, F., Billi, J. E., Callaway, C. W., … Zideman, D. A. (2015). Part 
1: Executive Summary: 2015 International Consensus on Cardiopulmonary Resuscitation and 
Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation, 132(16 
Suppl 1), S2-39. http://doi.org/10.1161/CIR.0000000000000270 
Herridge, M. L., Stimler, C. E., Southard, D. R., & King, M. L. (2005). Depression screening in cardiac 
rehabilitation: AACVPR Task Force Report. Journal of Cardiopulmonary Rehabilitation, 25(1), 11–13. 
http://doi.org/10.1097/00008483-200501000-00003 
Ho, P. M., Bryson, C. L., & Rumsfeld, J. S. (2009). Medication Adherence: Its Importance in Cardiovascular 
Outcomes. Circulation, 119(23), 3028–3035. http://doi.org/10.1161/CIRCULATIONAHA.108.768986 
Honig, A., Kuyper, A. M. G., Schene, A. H., van Melle, J. P., de Jonge, P., Tulner, D. M., … Ormel, J. (2007). 
Treatment of Post-Myocardial Infarction Depressive Disorder: A Randomized, Placebo-Controlled 
Trial With Mirtazapine. Psychosomatic Medicine, 69(7), 606–613. 
http://doi.org/10.1097/PSY.0b013e31814b260d 
Huffman, J. C., Beale, E. E., Celano, C. M., Beach, S. R., Belcher, A. M., Moore, S. V., … Januzzi, J. L. (2016). 
Effects of Optimism and Gratitude on Physical Activity, Biomarkers, and Readmissions After an 
Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes, 9(1), 55–63. 
http://doi.org/10.1161/CIRCOUTCOMES.115.002184 
Huffman, J. C., Mastromauro, C. a, Beach, S. R., Celano, C. M., DuBois, C. M., Healy, B. C., … Januzzi, J. L. 
(2014). Collaborative Care for Depression and Anxiety Disorders in Patients With Recent Cardiac 
 58  
Events. JAMA Internal Medicine, 174(6), 927. http://doi.org/10.1001/jamainternmed.2014.739 
Hughes, A. R., Mutrie, N., & Macintyre, P. D. (2007). Effect of an exercise consultation on maintenance 
of physical activity after completion of phase III exercise-based cardiac rehabilitation. European 
Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of 
Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise 
Physiology, 14(1), 114–21. http://doi.org/10.1097/HJR.0b013e3280116485 
Khawaja, I. S., Westermeyer, J. J., Gajwani, P., & Feinstein, R. E. (2009). Depression and coronary artery 
disease: the association, mechanisms, and therapeutic implications. Psychiatry (Edgmont (Pa. : 
Township)), 6(1), 38–51. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19724742 
Knadler, M. P., Lobo, E., Chappell, J., & Bergstrom, R. (2011). Duloxetine: clinical pharmacokinetics and 
drug interactions. Clinical Pharmacokinetics, 50(5), 281–94. http://doi.org/10.2165/11539240-
000000000-00000 
Koszycki, D., Lafontaine, S., Frasure-Smith, N., Swenson, R., & Lespérance, F. (2004). An Open-Label Trial 
of Interpersonal Psychotherapy in Depressed Patients With Coronary Disease. Psychosomatics, 
45(4), 319–324. http://doi.org/10.1176/appi.psy.45.4.319 
Kourkoveli, P., Rammos, S., Parissis, J., Maillis, A., Kremastinos, D., & Paraskevaidis, I. (2015). Depressive 
Symptoms in Patients with Congenital Heart Disease: Incidence and Prognostic Value of Self-Rating 
Depression Scales. Congenital Heart Disease, 10(3), 240–247. http://doi.org/10.1111/chd.12200 
Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: validity of a brief depression severity 
measure. Journal of General Internal Medicine, 16(9), 606–13. 
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2003). The Patient Health Questionnaire-2. Medical Care, 
41(11), 1284–1292. http://doi.org/10.1097/01.MLR.0000093487.78664.3C 
Lambert, G., Johansson, M., Ågren, H., & Friberg, P. (2000). Reduced Brain Norepinephrine and 
Dopamine Release in Treatment-Refractory Depressive Illness. Archives of General Psychiatry, 
57(8), 787. http://doi.org/10.1001/archpsyc.57.8.787 
Lavie, C. J., Arena, R., Swift, D. L., Johannsen, N. M., Sui, X., Lee, D.-C., … Blair, S. N. (2015). Exercise and 
the Cardiovascular System: Clinical Science and Cardiovascular Outcomes. Circulation Research, 
117(2), 207–19. http://doi.org/10.1161/CIRCRESAHA.117.305205 
 59  
Lavie, C. J., Morshedi-Meibodi, A., & Milani, R. V. (2008). Impact of cardiac rehabilitation on coronary 
risk factors, inflammation, and the metabolic syndrome in obese coronary patients. Journal of the 
Cardiometabolic Syndrome, 3(3), 136–140. 
Lespérance, F., Frasure-Smith, N., Koszycki, D., Laliberté, M.-A., van Zyl, L. T., Baker, B., … MD, M. (2007). 
Effects of Citalopram and Interpersonal Psychotherapy on Depression in Patients With Coronary 
Artery Disease. JAMA, 297(4), 367. http://doi.org/10.1001/jama.297.4.367 
Lett, H. S., Blumenthal, J. A., Babyak, M. A., Sherwood, A., Strauman, T., Robins, C., & Newman, M. F. 
(2004). Depression as a risk factor for coronary artery disease: evidence, mechanisms, and 
treatment. Psychosomatic Medicine, 66(3), 305–15. 
Lichtman, J. H., Bigger, J. T., Blumenthal, J. a, Frasure-Smith, N., Kaufmann, P. G., Lespérance, F., … 
Froelicher, E. S. (2008). Depression and coronary heart disease: recommendations for screening, 
referral, and treatment: a science advisory from the American Heart Association Prevention 
Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on. 
Circulation, 118(17), 1768–75. http://doi.org/10.1161/CIRCULATIONAHA.108.190769 
Lichtman, J. H., Froelicher, E. S., Blumenthal, J. A., Carney, R. M., Doering, L. V., Frasure-Smith, N., … 
Wulsin, L. (2014). Depression as a Risk Factor for Poor Prognosis Among Patients With Acute 
Coronary Syndrome: Systematic Review and Recommendations: A Scientific Statement From the 
American Heart Association. Circulation, 129(12), 1350–1369. 
http://doi.org/10.1161/CIR.0000000000000019 
Lowe B, Unutzer J, Callahan CM, Perkins AJ, K. K. (2004). Monitoring depression treatment outcomes 
with the patient health questionnaire-9. Med Care, 42(12), 1194–1201. 
MacGillivray, S., Arroll, B., Hatcher, S., Ogston, S., Reid, I., Sullivan, F., … Bush, T. (2003). Efficacy and 
tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in 
depression treated in primary care: systematic review and meta-analysis. BMJ (Clinical Research 
Ed.), 326(7397), 1014. http://doi.org/10.1136/bmj.326.7397.1014 
Marzolini, S., Leung, Y. W., Alter, D. a., Wu, G., & Grace, S. L. (2013). Outcomes associated with cardiac 
rehabilitation participation in patients with musculoskeletal comorbidities. European Journal of 
Physical and Rehabilitation Medicine, 49(6), 775–783. Retrieved from 
http://www.scopus.com/inward/record.url?eid=2-s2.0-84896327368&partnerID=tZOtx3y1 
 60  
Mathers, Colin, Stevens, Gretchen, Mascarenhas, M. (2009). Global Health Risks: Mortality and burden 
of disease attributable to selected major risks. 
Mccreery, C., Cradock, K., Fallon, N., Duffy, R., Doherty, V. O., & Kingston, C. (2013). Cardiac 
Rehabilitation Guidelines IACR Cardiac Rehabilitation Guidelines. 
Melton, L. J. (1996). History of the Rochester Epidemiology Project. Mayo Clinic Proceedings. Mayo 
Clinic, 71(3), 266–274. http://doi.org/10.4065/71.3.266 
Milani, R. V., & Lavie, C. J. (2007). Impact of Cardiac Rehabilitation on Depression and Its Associated 
Mortality. The American Journal of Medicine, 120(9), 799–806. 
http://doi.org/10.1016/j.amjmed.2007.03.026 
Milani, R. V., Lavie, C. J., & Cassidy, M. M. (1996). Effects of cardiac rehabilitation and exercise training 
programs on depression in patients after major coronary events. American Heart Journal, 132(4), 
726–732. http://doi.org/10.1016/S0002-8703(96)90304-X 
Moret, C. (2005). Combination/augmentation strategies for improving the treatment of depression. 
Neuropsychiatric Disease and Treatment, 1(4), 301–9. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/18568111 
Mota-Pereira, J., Silverio, J., Carvalho, S., Ribeiro, J. C., Fonte, D., & Ramos, J. (2011). Moderate exercise 
improves depression parameters in treatment-resistant patients with major depressive disorder. 
Journal of Psychiatric Research, 45(8), 1005–11. http://doi.org/10.1016/j.jpsychires.2011.02.005 
National Heart Lung and Blood Institute. (2016). Summary of Assessment Recommendations. 
Nwokeji, E. D., Bohman, T. M., Wallisch, L., Stoner, D., Christensen, K., Spence, R. R., … Ostermeyer, B. 
(2012). Evaluating patient adherence to antidepressant therapy among uninsured working adults 
diagnosed with major depression: results of the Texas Demonstration to Maintain Independence 
and Employment study. Administration and Policy in Mental Health, 39(5), 374–82. 
http://doi.org/10.1007/s10488-011-0354-z 
O’Connor, C. M., Jiang, W., Kuchibhatla, M., Mehta, R. H., Clary, G. L., Cuffe, M. S., … Krishnan, R. R. 
(2008). Antidepressant Use, Depression, and Survival in Patients With Heart Failure. Archives of 
Internal Medicine, 168(20), 2232–2237. http://doi.org/10.1001/archinte.168.20.2232 
 61  
O’Connor, C. M., Jiang, W., Kuchibhatla, M., Silva, S. G., Cuffe, M. S., Callwood, D. D., … Krishnan, R. 
(2010). Safety and Efficacy of Sertraline for Depression in Patients With Heart Failure. Journal of 
the American College of Cardiology, 56(9), 692–699. http://doi.org/10.1016/j.jacc.2010.03.068 
Organization, W. H. (1992). The ICD-10 classification of mental and behavioural disorders  : clinical 
descriptions and diagnostic guidelines. Geneva : World Health Organization. 
Organization, W. H. (2000). Obesity: Preventing and Managing the Global Epidemic. World Health 
Organization. Retrieved from 
https://books.google.com/books?hl=en&lr=&id=AvnqOsqv9doC&pgis=1 
Pacher, P., & Kecskemeti, V. (2004). Cardiovascular side effects of new antidepressants and 
antipsychotics: new drugs, old concerns? Current Pharmaceutical Design, 10(20), 2463–75. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15320756 
Paul Dendale, Patrick Doherty, Dan Gaita, Stefan Höfer, Hannah McGee, Miguel Mendes, Josef Niebauer, 
N., & Massimo F Piepoli, Ugo Corrà, Stamatis Adamopoulos, Werner Benzer, Birna Bjarnason-
Wehrens, M. C. (2014). Cardiology Rehabilitation. Endorsed by the Committee for Practice 
Guidelines of the European Society of Cardiac Rehabilitation Section of the European Association 
for Cardiovascular Prevention & components, standards and outcome measures for referral and. 
European Journal of Preventive Cardiology, 21(664). 
Perk, J., De Backer, G., Gohlke, H., Graham, I., & Reiner, Z. (2012). European Guidelines on cardiovascular 
disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European 
Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. 
European Heart Journal, 33(13), 1635–1701. 
Ramasubbu, R., Taylor, V. H., Samaan, Z., Sockalingham, S., Li, M., Patten, S., … McIntyre, R. S. (2012). 
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations 
for the management of patients with mood disorders and select comorbid medical conditions. 
Annals of Clinical Psychiatry. 
Reddy, M. S. (2010). Depression: the disorder and the burden. Indian Journal of Psychological Medicine, 
32(1), 1–2. http://doi.org/10.4103/0253-7176.70510 
Roest, A. M., Carney, R. M., Freedland, K. E., Martens, E. J., Denollet, J., & de Jonge, P. (2013). Changes in 
 62  
cognitive versus somatic symptoms of depression and event-free survival following acute 
myocardial infarction in the Enhancing Recovery In Coronary Heart Disease (ENRICHD) study. 
Journal of Affective Disorders, 149(1–3), 335–41. http://doi.org/10.1016/j.jad.2013.02.008 
Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, W. M. (2009). Depressive symptoms and health-
related quality of life: the Heart and Soul Study. Angiology, 28, 92–99. 
Rutledge, T., Redwine, L. S., Linke, S. E., & Mills, P. J. (2013, May). A Meta-Analysis of Mental Health 
Treatments and Cardiac Rehabilitation for Improving Clinical Outcomes and Depression Among 
Patients With Coronary Heart Disease. http://doi.org/10.1097/PSY.0b013e318291d798 
Samartzis, L., Dimopoulos, S., Tziongourou, M., Koroboki, E., Kyprianou, T., & Nanas, S. (2013). SSRIs 
versus exercise training for depression in chronic heart failure: a meta-analysis of randomized 
controlled trials. International Journal of Cardiology, 168(5), 4956–8. 
http://doi.org/10.1016/j.ijcard.2013.07.143 
Scholz, U., Knoll, N., Sniehotta, F. F., & Schwarzer, R. (2006). Physical activity and depressive symptoms 
in cardiac rehabilitation: long-term effects of a self-management intervention. Social Science & 
Medicine (1982), 62(12), 3109–20. http://doi.org/10.1016/j.socscimed.2005.11.035 
Shanmugasegaram, S., Russell, K. L., Kovacs, A. H., Stewart, D. E., & Grace, S. L. (2012). Gender and sex 
differences in prevalence of major depression in coronary artery disease patients: A meta-analysis. 
Maturitas, 73(4), 305–311. Retrieved from 
http://resolver.scholarsportal.info/resolve/03785122/v73i0004/305_gasdipcadpam.xml 
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. a, Franklin, B. A., … Taubert, K. A. 
(2011). AHA / ACCF Guideline AHA / ACCF Secondary Prevention and Risk Reduction Therapy for 
Patients With Coronary and Other Atherosclerotic Vascular Disease : 2011 Update A Guideline 
From the American Heart Association and American College. Circulation, 124(22), 2458–73. 
http://doi.org/10.1161/CIR.0b013e318235eb4d 
Sniehotta, F. F., Scholz, U., Schwarzer, R., Fuhrmann, B., Kiwus, U., & Völler, H. (2005). Long-term effects 
of two psychological interventions on physical exercise and self-regulation following coronary 
rehabilitation. International Journal of Behavioral Medicine, 12(4), 244–55. 
http://doi.org/10.1207/s15327558ijbm1204_5 
 63  
St Sauver, J. L., Grossardt, B. R., Yawn, B. P., Melton, L. J., Pankratz, J. J., Brue, S. M., & Rocca, W. A. 
(2012). Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage 
system. International Journal of Epidemiology, 41(6), 1614–24. http://doi.org/10.1093/ije/dys195 
Stephen Waring, W. (2010). Clinical use of antidepressant therapy and associated cardiovascular risk. 
Drug, Healthcare and Patient Safety, 4(1), 97–104. http://doi.org/10.2174/157488610789869265 
Taylor, C., & Frasure-Smith, N. (1995). The Montreal Heart Attack Readjustment Trial. Journal of 
Cardiopulmonary. Retrieved from 
http://journals.lww.com/jcrjournal/Abstract/1995/03000/The_Montreal_Heart_Attack_Readjustm
ent_Trial_.2.aspx 
Thombs, B. D., Bass, E. B., Ford, D. E., Stewart, K. J., Tsilidis, K. K., Patel, U., … Ziegelstein, R. C. (2005). 
Prevalence of Depression in Survivors of Acute Myocardial Infarction. Journal of General Internal 
Medicine, 21(1), 30–38. http://doi.org/10.1111/j.1525-1497.2005.00269x.J 
Thombs, B. D., Roseman, M., Coyne, J. C., de Jonge, P., Delisle, V. C., Arthurs, E., … Smith, P. (2013). Does 
Evidence Support the American Heart Association’s Recommendation to Screen Patients for 
Depression in Cardiovascular Care? An Updated Systematic Review. PLoS ONE, 8(1), e52654. 
http://doi.org/10.1371/journal.pone.0052654 
Tully, P. (2015). Mixed Efficacy for Routine Depression Screening in Cardiac Surgery Patients: Six Month 
Follow-up On Hospital Readmissions, Quality of Life and Mental Health. European Psychiatry, 30. 
http://doi.org/10.1016/S0924-9338(15)30981-0 
Tully, P. J., Winefield, H. R., Baker, R. A., Denollet, J., Pedersen, S. S., Wittert, G. A., & Turnbull, D. A. 
(2015). Depression, anxiety and major adverse cardiovascular and cerebrovascular events in 
patients following coronary artery bypass graft surgery: a five year longitudinal cohort study. 
BioPsychoSocial Medicine, 9, 14. http://doi.org/10.1186/s13030-015-0041-5 
Turk-Adawi, K., Sarrafzadegan, N., & Grace, S. L. (2014). Global availability of cardiac rehabilitation. 
Nature Reviews Cardiology, 11(10), 586–596. http://doi.org/10.1038/nrcardio.2014.98 
van Melle, J. P., de Jonge, P., Spijkerman, T. A., Tijssen, J. G. P., Ormel, J., van Veldhuisen, D. J., … van den 
Berg, M. P. (2008). Prognostic association of depression following myocardial infarction with 
mortality and cardiovascular events: a meta-analysis. Psychosomatic Medicine, 66(6), 814–22. 
 64  
http://doi.org/10.1097/01.psy.0000146294.82810.9c 
Vanderkooy, J. D., Kennedy, S. H., & Bagby, R. M. (2002). Antidepressant side effects in depression 
patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, 
sertraline, and venlafaxine. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie, 47(2), 
174–80. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11926080 
Veien, K. T., Videb??k, L., Schou, M., Gustafsson, F., Hald-Steffensen, F., & Hildebrandt, P. R. (2011). High 
mortality among heart failure patients treated with antidepressants. International Journal of 
Cardiology, 146(1), 64–67. http://doi.org/10.1016/j.ijcard.2010.01.006 
Vieweg, W. V. R., Hasnain, M., Lesnefsky, E. J., & Pandurangi, A. K. (2011). Review of major measuring 
instruments in comorbid depression and coronary heart disease. Progress in Neuro-
Psychopharmacology & Biological Psychiatry, 35(4), 905–12. 
http://doi.org/10.1016/j.pnpbp.2011.03.009 
Weiner, D. E., Tighiouart, H., Stark, P. C., Amin, M. G., MacLeod, B., Griffith, J. L., … Sarnak, M. J. (2004). 
Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. American Journal 
of Kidney Diseases, 44(2), 198–206. http://doi.org/10.1053/j.ajkd.2004.04.024 
Woodruffe, S., Neubeck, L., Clark, R. A., Gray, K., Ferry, C., Finan, J., … Briffa, T. G. (2014). Australian 
Cardiovascular Health and Rehabilitation Association (ACRA) Core Components of Cardiovascular 
Disease Secondary Prevention and Cardiac Rehabilitation 2014. Heart, Lung and Circulation. 
http://doi.org/10.1016/j.hlc.2014.12.008 
Yekehtaz, H., Farokhnia, M., & Akhondzadeh, S. (2013). Cardiovascular considerations in antidepressant 
therapy: an evidence-based review. The Journal of Tehran Heart Center, 8(4), 169–76. Retrieved 
from http://www.ncbi.nlm.nih.gov/pubmed/26005484 
Yusuf, S., Reddy, S., Ounpuu, S., & Anand, S. (2001). Global Burden of Cardiovascular Diseases: Part I: 
General Considerations, the Epidemiologic Transition, Risk Factors, and Impact of Urbanization. 
Circulation, 104(22), 2746–2753. http://doi.org/10.1161/hc4601.099487 
Zemrak, W. R., & Kenna, G. A. (2008). Association of antipsychotic and antidepressant drugs with Q-T 
interval prolongation. American Journal of Health-System Pharmacy : AJHP : Official Journal of the 
American Society of Health-System Pharmacists, 65(11), 1029–38. 
 65  
http://doi.org/10.2146/ajhp070279 
Zhang, P. (2015). Study of Anxiety/Depression in Patients with Coronary Heart Disease After 
Percutaneous Coronary Intervention. Cell Biochemistry and Biophysics, 72(2), 503–507. 
http://doi.org/10.1007/s12013-014-0495-2 
Ziegelstein, R. C., Thombs, B. D., Coyne, J. C., & de Jonge, P. (2009). Routine Screening for Depression in 
Patients With Coronary Heart Disease. Journal of the American College of Cardiology, 54(10), 886–
890. http://doi.org/10.1016/j.jacc.2009.01.082 
Zimmermann-Viehoff, F., Kuehl, L. K., Danker-Hopfe, H., Whooley, M. A., & Otte, C. (2014). 
Antidepressants, autonomic function and mortality in patients with coronary heart disease: data 




 66  
FIGURE 1. DEPRESSIVE SYMPTOMS PRE AND POST-CARDIAC REHABILITATION BY ANY 
ANTIDEPRESSANT USE. 
 
Notes: t-test pre-CR p=<0.001; post-CR p=<0.001; ANOVA 2 (antidepressant status) x 2 (time), 
p<0.001. 
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FIGURE 2: KAPLAN-MEIER HAZARD RATES OF DEVELOPING ANY MAJOR ADVERSE CORONARY 
EVENT BY TRICYCLIC ANTIDEPRESSANT USE  
 
 
TCA= Tricyclic antidepressants 
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TABLE 1. PARTICIPANTS’ PRE-CR CLINICAL AND SOCIODEMOGRAPHIC CHARACTERISTICS BY 
RETENTION STATUS. 
 
SD = standard deviation. 
*p<.05; **p<.01; ***p<.001 






Sociodemographic    
Age, years (mean±SD) 65.22±12.32 63.89±12.88 64.23±12.75 
Sex, (% female) 103 (24.1) 444 (33.3) 537 (31.7) 
Race / ethnicity, (% white) 388 (90.7) 1191 (94.1) 1579 (93.2) 
Clinical (% yes)    
Cardiovascular Indication    
Percutaneous Coronary Intervention 251 (58.6) 715 (56.2) 966 (57.0) 
Peripheral Vascular Disease 121 (28.3) 443 (34.8)  564 (33.3)** 
Coronary Artery Bypass Graft 110 (25.7) 325 (25.5) 435  (25.7) 
Stroke 86 (20.1) 289 (22.8)  375 (22.1)* 
Heart Failure 38 (8.9) 193 (15.2) 231 (13.6)** 
Risk factors    
Dyslipidemia 394 (92.1) 1175 (92.8) 1569 (92.6) 
Hypertension  302 (70.6) 936 (73.5) 1238 (73.1) 
Diabetes 191 (44.6) 633 (49.7) 824 (48.6) 
Smoking History  152 (35.5) 556 (43.7) 708 (41.8)** 
Body Mass Index (mean±SD) 29.9±6.56 35.25±5.54 33.9±6.24 
Comorbidities    
Chronic Obstructive Pulmonary Disease 76 (17.8) 241 (18.9) 317 (18.7) 
Cancer 72 (16.8) 237 (18.6) 309 (18.2) 
Chronic Kidney Disease 22 (5.1) 110 (8.6) 132 (7.8)*** 
Psychological    
Depressive symptoms (mean± SD) 5.06±5.29 3.37±4.13 4.67±5.09*** 
Antidepressant Use (% yes) 140 (32.7) 433 (34.2) 573 (33.8)*** 
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Table 2. Depressive Symptoms pre and post-Cardiac Rehabilitation, N=1266. 
 
*paired t-test; †chi-square; ‡provisional based on PHQ-9 scoring. 
CR=cardiac rehabilitation; SD=standard deviation; PHQ=Patient Health Questionnaire 
  
 Pre-CR Post-CR p 
Total PHQ-9 Score (mean±SD) 4.98±5.19 3.57±4.43 <.001* 
Depressive Symptom Severity, n (%) 
Minimal (1-4) 758 (59.9) 907 (71.2) <.001* 
Mild (5-9) 284 (22.4) 234 (18.4)  
Moderate (10-14) 135 (10.7) 80 (6.8)  
Moderately severe (15-19) 54 (4.3) 30 (2.4)  
Severe (20-27) 31 (2.5) 15 (1.2)  
Diagnostic Criteria‡, n (%) 
Major Depression 67 (5.3) 24 (1.4) <.001* 
Other Depressive disorder 24 (1.9) 67 (4.0) <.001† 
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TABLE 3. OCCURRENCE OF MAJOR ADVERSE CORONARY EVENTS BY ANTIDEPRESSANT CLASS. 
















56 (18.7)** 38 
(21.2)** 
25 (24.5)** 16 (25.8)** 177 (14.0)** 
Angina 53 
(17.7)*** 
29 (16.2) 20 (16.7)* 13 (20.1)* 152 (12.0) 
Myocardial Infarction 37 (12.4)** 17 (9.4) 14 (13.7)* 6 (9.7) 99 (7.8)* 
Death 29 (9.7) 16 (8.9) 16 (15.7)** 7 (11.3) 96 (7.6) 
Heart Failure 28 (9.6)** 12 (6.7) 12 (11.8)* 7 (11.3) 78 (6.2) 
Coronary Artery Bypass 
Graft 
19 (6.4)* 8 (4.5) 6 (5.9) 3 (4.8) 50 (3.9)* 
Ventricular Arrhythmia 5 (1.0) 4 (2.2)*† 2 (2.0) 1 (1.6) 11 (0.9) 






38 (11.5)** 20 (6.1) 225 
(17.8)*** 




46 (11.8)** 24 (6.1) 264 
(20.9)*** 
Chi-square tests *p<.05; **p<.01; ***p<.001. 
CR= Cardiac Rehabilitation; SSRI= Selective Serotonin Reuptake Inhibitors; TCAs= Tricyclic 
antidepressants; SNRIs= Serotonin Norepinephrine Reuptake Inhibitors. 
†caution is warranted in over-interpreting this association, due to the small cell size.  
‡*reported in this column reflect association of each MACE with use of any antidepressant (i.e., 
many participants on ≥1).  
§number of MACEs overall.   
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TABLE 4. COX REGRESSION MODEL OF FACTORS ASSOCIATED WITH OCCURRENCE OF ANY 
MAJOR ADVERSE CORONARY EVENT INCLUDING DEATH 
 
 
CR= Cardiac Rehabilitation, CI=confidence interval.  
  
    95% CIs 




Peripheral Vascular Disease 4.74 .03 1.64 1.05 2.57 
Stroke 0.32 .57 1.14 0.72 1.81 
Heart Failure 6.10 .01 2.13 1.17 3.87 
Chronic Kidney Disease 0.92 .34 1.43 0.69 2.97 
History of Smoking 0.22 .64 1.11 0.73 1.67 
Pre-CR depressive symptoms  0.30 .58 1.01 0.97 1.05 
Tricyclic antidepressants 4.75 .03 1.93 1.07 3.49 
Selective Serotonin Reuptake Inhibitors 1.26 .26 1.32 0.81 2.13 
Serotonin-Norepinephrine Reuptake 
Inhibitors  
1.75 .19 2.28 0.67 7.71 
Atypical antidepressants  2.14 .14 1.42 0.89 2.29 
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Over the last 2 weeks, how often have you been bothered by any of the following problems? 
 




























































6. Feeling bad about yourself — or that you are a failure or 







7. Trouble concentrating on things, such as reading the 







8. Moving or speaking so slowly that other people could have 
noticed? Or the opposite — being so fidgety or restless               0               1              2              3 
that you have been moving around a lot more than usual 
9. Thoughts that you would be better off dead or of hurting 






3   
  
P A T I E N T  H E A L T H  Q U E S T I O N N A I R E - 9 ( P H Q - 9 )  
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APPENDIX B- ANTIDEPRESSANT RECOMMENDATIONS IN CVD PATIENTS BY CLASS 
Antidepressant Class Examples Recommendations in 
CVD Patients 
SSRIs Citalopram, Escitalopram,  Yes; first-line agents 
SNRIs Duloxetine, Venlafaxine Yes; second-line only 
Atypicals Mirtazapine, Bupropion, 
Trazodone 








SSRI= selective serotonin reuptake inhibitor; SNRI= serotonin-norepinephrine reuptake inhibitor; TCA= tricyclic 
antidepressants; MAOI= monoamine oxidase inhibitor. 
(Yekehtaz et al., 2013)  
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APPENDIX C- DEPRESSION SCREENING TOOLS RECOMMENDED BY VARIOUS ASSOCIATIONS Association Screening Tool Recommendations Citation American Heart Association PHQ-9 ( Kroenke et al., 2001)* (Judith H Lichtman et al., 2008) American Association of Cardiovascular Rehabilitation and Prevention 
BDI-2 (Ceccarini et al., 2014), PHQ-9 (Herridge et al., 2005) 
National Heart Lung and Blood Institute 
BDI-2, BDI-9 (Ceccarini et al., 2014) (National Heart Lung and Blood Institute, 2016) 
British Association for Cardiovascular Prevention and Rehabilitation 
Screening recommended with appropriate tool (unspecified) 
(Buckley et al., 2013)  
International Collaboration in Cardiovascular Prevention and Rehabilitation 
Screening recommended with appropriate tool (unspecified) 
(Grace et al., 2013, 2016) 
Irish Association of Cardiac Rehabilitation 
No tool recommended (Mccreery et al., 2013) 
Canadian Association of  Cardiovascular Prevention and  Rehabilitation 
PHQ-2 (CACPR, 2016) 
European Society No tool recommended  (Perk, De Backer, Gohlke, Graham, & Reiner, 
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of  Cardiology  2012) Australian Cardiovascular Health and Rehabilitation Association 
Screening recommended with appropriate tool (unspecified) 
(Woodruffe et al., 2014) 
 
*Both the first instance of a screening tool has been cited, as well as each of the depression screening guidelines 
for cardiac patients.  
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 APPENDIX D- FROM DEPRESSION TO MACE IN CARDIAC PATIENTS: CONCEPTUAL DIAGRAM  





















• Drastic change 
in sense of self 







Precipitating Factors leading to CVD in CR patients. 
Moderating Factors: risk factors, blood pressure, arrhythmias, drug-drug interactions 
